atos20190331

0001437749-19-009666.txt : 20190513 0001437749-19-009666.hdr.sgml : 20190513 20190513163230 ACCESSION NUMBER: 0001437749-19-009666 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190513 DATE AS OF CHANGE: 20190513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATOSSA GENETICS INC CENTRAL INDEX KEY: 0001488039 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264753208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35610 FILM NUMBER: 19818821 BUSINESS ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 206.588.0256 MAIL ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 10-Q 1 atos20190331_10q.htm FORM 10-Q atos20190331_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-35610

ATOSSA GENETICS INC.

(Exact name of registrant as specified in its charter)

Delaware	26-4753208
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

107 Spring Street	98104
Seattle, WA	(Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code: (206) 325-6086

Securities registered pursuance to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.18 par value	ATOS	NASDAQ

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s common stock, $0.18 par value per share, outstanding at May 9, 2019, was 9,124,732.

ATOSSA GENETICS INC.

FORM 10-Q

QUARTERLY REPORT

INDEX

PART I. FINANCIAL INFORMATION		3

ITEM 1.	Condensed Consolidated Financial Statements – Unaudited	3

	Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018	3

	Condensed Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018	4

	Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2019 and 2018	5

	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018	6

	Notes to Condensed Consolidated Financial Statements	7

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

ITEM 3	Quantitative and Qualitative Disclosures about Market Risk	17

ITEM 4.	Controls and Procedures	17

PART II. OTHER INFORMATION		18

ITEM 1.	Legal Proceedings	18

ITEM 1A.	Risk Factors	18

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18

ITEM 3.	Defaults upon Senior Securities	18

ITEM 4.	Mine Safety Disclosures	18

ITEM 5.	Other Information	18

ITEM 6.	Exhibits	19

SIGNATURES		20

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	As of March 31,
	2019			As of December 31,
Assets	(Unaudited)			2018
Current assets
Cash and cash equivalents	$	19,568,247		$	10,380,493
Restricted cash		110,000			110,000
Prepaid expenses		835,468			509,833
Research and development tax rebate receivable		237,856			518,098
Other current assets		27,957			30,942
Total current assets		20,779,528			11,549,366

Furniture and equipment, net		48,212			54,487
Intangible assets, net		91,667			99,375
Right-of-use asset		88,103
Other assets		17,218			17,218
Total Assets	$	21,024,728		$	11,720,446

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	463,970		$	353,328
Accrued expenses		74,844			177,074
Payroll liabilities		891,758			935,070
Stock-based compensation liability					1,410,025
Lease liability		50,706
Other current liabilities		9,863			39,939
Total current liabilities		1,491,141			2,915,436
Long term liabilities
Lease liability long term		37,397
Total Liabilities		1,528,538			2,915,436

Commitments and contingencies (note 11)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized; 702 and 2,379 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively		1			2
Additional paid-in capital- Series B convertible preferred stock		701,999			2,378,997
Common stock - $0.18 par value; 175,000,000 shares authorized, and 9,122,171 and 5,846,552 shares issued and outstanding, as of March 31, 2019 and December 31, 2018, respectively		1,641,979			1,052,372
Additional paid-in capital		98,056,781			82,204,902
Accumulated deficit		(80,904,570	)		(76,831,263	)
Total Stockholders' Equity		19,496,190			8,805,010

Total Liabilities and Stockholders' Equity	$	21,024,728		$	11,720,446

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months Ended March 31,
	2019			2018

Operating expenses
Research and development	$	1,451,236		$	470,976
General and administrative		2,613,093			1,403,465
Total operating expenses		4,064,329			1,874,441
Operating loss		(4,064,329	)		(1,874,441	)
Other income (expense)		(8,978	)		59
Loss before income taxes		(4,073,307	)		(1,874,382	)
Income taxes
Net loss	$	(4,073,307	)	$	(1,874,382	)
Loss per common share - basic and diluted	$	(0.62	)	$	(8.48	)
Weighted average shares outstanding - basic and diluted		6,565,514			220,996

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)



	Series B Convertible Preferred Stock			Common Stock
	Shares	Amount	Additional Paid-in Capital	Shares		Amount		Additional Paid-in Capital			Accumulated Deficit			Total Stockholders' Equity
Balance at December 31, 2017		$	$		220,996	$	477,342	$	71,887,674		$	(65,426,329	)	$	6,938,687
Amortization of commitment shares									(19,852	)					(19,852	)
Compensation cost for stock options granted									215,139						215,139
Net loss												(1,874,382	)		(1,874,382	)
Balance at March 31, 2018		$	$		220,996	$	477,342	$	72,082,961		$	(67,300,711	)	$	5,259,592

	Series B Convertible Preferred Stock									Common Stock
	Shares			Amount			Additional Paid-in Capital			Shares		Amount		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Equity
Balance at December 31, 2018		2,379		$	2		$	2,378,997			5,846,552	$	1,052,372	$	82,204,902	$	(76,831,263	)	$	8,805,010
Issuance of common stock upon warrant exercise											2,799,188		503,854		10,832,856					11,336,710
Conversion of Series B convertible preferred stock to common stock		(1,677	)		(1	)		(1,676,998	)		476,431		85,753		1,591,246
Reclassification of stock-based liability awards to equity upon cancellation															3,151,944					3,151,944
Compensation cost for stock options granted															275,833					275,833
Net loss																	(4,073,307	)		(4,073,307	)
Balance at March 31, 2019		702		$	1		$	701,999			9,122,171	$	1,641,979	$	98,056,781	$	(80,904,570	)	$	19,496,190

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Three Months Ended March 31,
	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(4,073,307	)	$	(1,874,382	)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted		275,833			215,139
Depreciation and amortization		13,983			7,864
Change in fair value of stock-based compensation liability		1,741,919			-
Changes in operating assets and liabilities:
Prepaid expenses		(325,635	)		(244,723	)
Research and development tax rebate receivable		280,242			(37,595	)
Other assets		2,985			51,512
Accounts payable		110,642			(166,554	)
Payroll liabilities		(43,312	)		(428,440	)
Accrued expenses		(102,230	)		82,508
Other current liabilities		(30,076	)		7,789
Net cash used in operating activities		(2,148,956	)		(2,386,882	)

CASH FLOWS FROM INVESTING ACTIVITY
Purchase of furniture and equipment					(51,068	)
Net cash used in investing activities					(51,068	)

CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from exercise of warrants		11,336,710
Net cash provided by financing activities		11,336,710

NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH		9,187,754			(2,437,950	)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE		10,490,493			7,272,469
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	$	19,678,247		$	4,834,519

SUPPLEMENTAL DISCLOSURES
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	$	19,568,247		$	4,779,519
Restricted cash		110,000			55,000
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$	19,678,247		$	4,834,519

NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of stock-based liability awards to equity upon cancellation	$	3,151,944
Amortization of commitment shares	$			$	19,852

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATOSSA GENETICS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1: NATURE OF OPERATIONS

Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is focused on development of its pharmaceutical and drug delivery programs.

NOTE 2: LIQUIDITY AND CAPITAL RESOURCES

The Company has incurred net losses and negative operating cash flows since inception. For the three months ended March 31, 2019, the Company recorded a net loss of approximately $4.1 million and used approximately $2.1 million of cash in operating activities. As of March 31, 2019, the Company had approximately $19.6 million in cash and cash equivalents and working capital of approximately $19.3 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and is currently expending funds in research and development activities that are expected to continue to require funding. Management believes the currently available funding will be sufficient to finance the Company’s operations for at least one year from the date of these Condensed Consolidated Financial Statements. However, the Company will likely require additional funding to continue its activities beyond that date. If adequate funds are not available, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned commercial activities. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

NOTE 3: SUMMARY OF ACCOUNTING POLICIES

Basis of Presentation:

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2018.

In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2019, are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.

Use of Estimates:

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Recently Adopted Accounting Pronouncements:

In the first quarter of 2019, we adopted Accounting Standards Update (“ASU”) No. 2016-02, Lease Accounting Topic 842: ("Topic 842") and recognized on our Condensed Consolidated Balance Sheet $101,000 of lease liabilities with corresponding right-of-use assets for operating leases. The new lease standard requires a lessee to measure its operating lease liabilities at the present value of the remaining minimum lease payments with a discounted cash flow model using the interest rate implicit in the lease. If the implicit interest rate cannot be readily determined, the lessee must use its incremental borrowing rate (“IBR”). If the lessee does not have an IBR, the lessee must use a rate that approximates the rate of interest that the lessee would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. The implicit interest rate was readily determinable for our copier lease; however, we used an IBR to measure our adoption date operating lease liability related to our office space which rate represents our estimated borrowing rate on a secured loan collateralized by similar assets for a similar term. The adoption did not have an impact on the Condensed Consolidated Statements of Cash Flows. As permitted under the standard, we elected prospective application of the new guidance and prior periods continue to be presented in accordance with Accounting Standards Codification ("ASC") Topic 840. Refer to our 2018 Annual Report on Form 10-K for disclosures required by Topic 840. The new standard provides a number of optional practical expedients in transition. We elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, to not separate lease and non lease components and to not reassess initial direct costs. We did not elect the practical expedient allowing the use-of-hindsight which would require us to reassess the lease term of its leases based on all facts and circumstances through the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to our current contract portfolio. See Note 11, Commitments and Contingencies, of the notes to our unaudited condensed consolidated financial statements for additional discussion of our leases and the amounts recognized in these unaudited condensed consolidated financial statements.

On January 1, 2019, we adopted ASU 2018-08, Not-for-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made. This ASU affects not-for-profit entities and business entities that receive or make contributions of cash. The ASU clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic 958 or as an exchange transaction subject to other guidance. The adoption did not have any impact on the financial statements.

Recent Accounting Pronouncements:

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. Furthermore, an entity is permitted to early adopt any removed or modified disclosures upon issuance of the update and delay adoption of the additional disclosures until their effective date. We do not expect this amendment to have a material impact on our consolidated financial statements.

NOTE 4: PREPAID EXPENSES

Prepaid expenses consisted of the following:

	March 31,		December 31,
	2019		2018
Prepaid insurance	$	234,875	$	160,576
Prepaid research and development		392,894		218,090
Professional services		96,250		110,094
Financial exchange fees		58,685
Prepaid rent		17,100
Retainer and security deposits		14,218		16,718
Other		21,446		4,355
Total prepaid expenses	$	835,468	$	509,833

NOTE 5: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase 1 and Phase 2 Endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the three months ended March 31, 2019 and 2018, the Company incurred qualified R&D expenses of approximately $80,000 and $86,000, respectively. The Company recorded a rebate receivable of approximately $35,000 and $38,000 for the three months ended March 31, 2019 and 2018, respectively and a corresponding credit to R&D expenses. At March 31, 2019, we had a total R&D rebate receivable of approximately $238,000 that includes approximately $203,000 receivable remaining from the year ended December 31, 2018.

NOTE 6: PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	March 31, 2019		December 31, 2018
Accrued bonuses	$	646,433	$	697,995
Accrued vacation		162,619		160,740
Accrued payroll		82,706		76,335
Total payroll liabilities	$	891,758	$	935,070

NOTE 7: STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of 185,000,000 shares of stock consisting of 175,000,000 shares of common stock, par value $0.18 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A junior participating preferred stock, par value $0.001 per share, 4,000 shares of Series A convertible preferred stock, par value $0.001 per share, and 25,000 shares of Series B convertible preferred stock, par value $0.001 per share, through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock and no shares of Series A convertible preferred stock are issued and outstanding as of March 31, 2019.

2018 Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants

On May 30, 2018, the Company completed a rights offering pursuant to which the Company sold an aggregate of 13,624 units consisting of an aggregate of 13,624 shares of Series B convertible preferred stock and 3,869,216 warrants, with each warrant exercisable for one share of common stock at an exercise price of $4.05 per share (the “2018 Warrants”), resulting in net proceeds to the Company of approximately $12.3 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.

Warrants

As of March 31, 2019, 1,070,028 warrants to purchase shares of common stock were outstanding. The warrants have an exercise price of $4.05 and expire on May 30, 2022.

For the three months ended March 31, 2019, the Company received approximately $11.3 million from exercises of the 2018 Warrants. As a result of the warrant exercises, the Company issued approximately 2.8 million warrants and issued approximately 2.8 million shares of common stock.

Conversion of Series B Convertible Preferred Stock

During the three months ended March 31, 2019, certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of 1,677 shares into 476,431 shares of the Company's common stock based on the conversion ratio of approximately 284 shares of common stock for each share of Series B convertible preferred stock.

NOTE 8: NET LOSS PER SHARE

The Company accounts for and discloses net loss per common share in accordance with ASC Topic 260, Earnings Per Share. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.

The following table summarizes the Company’s calculation of net loss per common share:

	Three Months Ended March 31,
	2019			2018
Numerator
Net loss attributable to common shareholders	$	(4,073,307	)	$	(1,874,382	)
Denominator
Weighted average common shares outstanding used to compute net loss per share, basic and diluted		6,565,514			220,996
Net loss per share of common stock, basic and diluted:	$	(0.62	)	$	(8.48	)

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three months ended March 31, 2019 and 2018 because including them would be anti-dilutive:

	Three Months Ended March 31,
	2019		2018
Options to purchase common stock		783,383		14,473
Series B convertible preferred stock		458,994
Warrants to purchase common stock		3,369,468		76,235
		4,611,845		90,708

NOTE 9: INCOME TAXES

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of March 31, 2019 and December 31, 2018, due to the Company’s continuing operating losses.

NOTE 10: CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At March 31, 2019 and December 31, 2018, the Company had $18,925,000 and $10,052,000 in excess of the FDIC insured limit, respectively.

NOTE 11: COMMITMENTS AND CONTINGENCIES

Lease Commitments

As discussed in Note 3, we adopted the requirements of ASU No. 2016-02, Lease Accounting: Topic 842, and all related amendments on January 1, 2019. Prior to January 1, 2019, we accounted for leases in accordance with ASC Topic 840, Leases. In accordance with Topic 842, we evaluate all contractual agreements at inception to determine if they contain a lease. We measure lease liabilities at present value of lease payments not yet paid, using a discounted cash flow model that requires the use of a discount rate, or incremental borrowing rate.

Our operating lease assets consist of an office lease and a copier system lease. Our office lease expires in August of 2020 and our copier system lease expires in October of 2021. None of our leases contain options to extend. Total operating lease expense for the three months ended March 31, 2019, was approximately $12,900 and variable lease payments of taxes and insurance were immaterial. As of March 31, 2019, the weighted average remaining lease term was approximately 1.7 years and the weighted average discount rate of our operating leases was 12%.

As of March 31, 2019, the future minimum lease payments are approximately $44,000, $44,000 and $12,000 for 2019, 2020 and 2021, respectively. These payments are reported in the condensed consolidated balance sheets at March 31, 2019, net of approximately $12,000 of imputed interest. The cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2019 was approximately $14,600.

Litigation and Contingencies

We are subject to legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.

NOTE 12: STOCK BASED COMPENSATION

Stock Option and Incentive Plan

On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan the (“2010 Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 5,556 shares were initially reserved for issuance in connection with awards granted under the 2010 Plan and on May 18, 2016, an additional 11,111 shares were reserved for issuance under the 2010 Plan. On May 9, 2018, the stockholders approved an additional 125,000 shares for issuance under the 2010 Plan. On April 12, 2018, the stockholders approved an additional 500,000 shares for issuance under the 2010 Plan.

The following table presents the automatic additions to the 2010 Plan since inception pursuant to the “evergreen” terms of the 2010 Plan:

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		7,257
2017		12,623
2018		106,076
2019		233,862
Total additional shares		374,782

The Company did not grant options to purchase shares of common stock during the three months ended March 31, 2019 or 2018. No options were exercised during the three months ended March 31, 2019 or 2018. There are 236,430 shares available for grant under the 2010 Plan as of March 31, 2019.

Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $275,833 and $215,139 for the three months ended March 31, 2019 and 2018, respectively (excluding the liability options discussed below).

	Three Months Ended March 31,
	2019		2018
General and administrative	$	224,676	$	166,701
Research and development		51,157		48,438
Total stock compensation Expense	$	275,833	$	215,139

Options issued and outstanding as of March 31, 2019, under the 2010 Plan and their activities during the three months then ended are as follows:

	Number of Underlying Shares		Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2019		783,383	$	12.14
Granted
Forfeited
Expired
Outstanding as of March 31, 2019		783,383		12.14		8.92	$	695,400
Exercisable as of March 31, 2019		434,515		19.38		8.84	$	374,063
Vested and expected to vest		783,383	$	12.14		8.92	$	695,400

At March 31, 2019, there were 348,868 unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately $876,533. This expense is expected to be recognized over a weighted-average period of 1.40 years.

2018 Liability Options

On June 27, 2018, the Company granted 2,300,000 options to the Chief Executive Officer (CEO) and 700,000 to the Chief Financial Officer (CFO) (the "Liability Options"). Each option was exercisable for an equivalent number of shares of Company's common stock. The Liability Options were granted pursuant to an option award agreement and were granted outside the Company’s 2010 Plan; however, they were subject to the terms and conditions of the 2010 Plan. On January 13, 2019, the Liability Options were canceled.

The Liability Options were exercisable for shares of common stock at an exercise price of $2.38 per share, which was the fair value on the date of grant. The options had an exercise period of ten years from their date of issuance. If at the time the options were exercised the Company could not deliver shares of common stock to the optionee including, for example, if there were insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option only would be exercised on a cash “net basis” so that the Company would pay cash in an amount equal to the excess of the fair value of the common stock over the option exercise price. If there were not sufficient shares available under the Plan, the Company would have been obligated to settle these options in cash if they were exercised. Because these options contained provisions that would require the Company to settle the options in cash in an event outside the Company’s control, they were accounted for as liabilities.

The Liability Options were subject to vesting requirements. Twenty-five percent of the options were vested as of the grant date, 50% of the options would have vested quarterly over two years, and the remaining 25% would have vested upon achievement of certain milestones related to clinical trial progress. As of January 13, 2019, all of the Liability Options that vested upon achievement of clinical trial milestones were vested. On January 13, 2019, the Liability Options were cancelled and at the time of cancellation, there were 1,125,000 unvested Liability Options outstanding.

Compensation costs associated with the Liability Options were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement.

At the time of cancellation, the fair value of Liability Options at January 13, 2019, was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	January 13,
	2019

Risk free interest rate		2.53	%
Expected term (in years)		4.50-5.00
Stock price	$	1.36
Dividend yield			%
Expected volatility		121.0-123.0	%

As a result of the cancellation, the Company recognized all remaining unrecognized compensation expense related to these options of $1,741,919, which was included in the following captions in the condensed consolidated statements of operations:

	Period Ended March 31, 2019

General and administrative	$	1,074,183
Research and development		667,736
Total stock compensation expense	$	1,741,919

Also on January 13, 2019, at the same time the Liability Options were cancelled, the Company awarded a new option to the CEO to purchase 2,300,000 shares of Common Stock and a new option to the CFO to purchase 800,000 shares of common stock (the “2019 Options”). The 2019 Options: (i) have an exercise price equal to the fair market value of Common Stock on the date of board of director approval which was $1.36 per share, (ii) do not contain a net cash exercise provision, (iii) are awarded pursuant to the terms and conditions of the 2010 Plan as amended by the Board of Directors on January 13, 2019, to include shares issuable upon exercise of the 2019 Options and other changes to the 2010 Plan so that the 2019 Options do not conflict with the 2010 Plan (the “Amended Plan”), (iv) vest and are exercisable in accordance with the vesting schedule related to the 2018 Liability Options; provided, however, that the 2019 Options are not exercisable unless and until the Company’s stockholders approve the Amended Plan to increase the authorized number of shares available for grant under the Plan and (vi) are subject to and conditioned upon the 2019 Option Agreements with the optionees and the employment agreements with the optionees.

The above actions were unanimously approved by the disinterested members of the Board of Directors. The above actions are intended to eliminate the Company’s potential liability associated with the net cash exercise provision of the liability options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the 2019 Options.

Accounting treatment

Awards offered under a plan that are subject to shareholder approval are not considered granted under GAAP until the approval is obtained, unless such approval is essentially a formality (or perfunctory). For example, if management and board members control sufficient votes to approve the plan, the vote may be considered perfunctory. As management and the Company’s Board of Directors do not control enough votes to approve the 2019 Options, the 2019 Options are not deemed granted under ASC 718. Cancellation of an award that is not accompanied by the concurrent grant are accounted for as a repurchase for no consideration. Accordingly, any previously unrecognized compensation cost is recognized at the cancellation date. On January 13, 2019, as noted above, the Company recognized $1,741,919 of unrecognized compensation cost related to the 2018 Liability Options. Additionally, the fair value of the stock-based compensation liability of $3,151,944 was reclassified to additional-paid in capital on the cancellation date. If shareholder approval is obtained and a grant date is established for the 2019 Options, the Company will measure and record them as a new grant under ASC 718.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of the financial condition and results of operations should be read in conjunction with the financial statements and the related notes included elsewhere in this report. This discussion contains forward-looking statements, which are based on assumptions about the future of the Company’s business. The actual results could differ materially from those contained in the forward-looking statements. Please read “Forward-Looking Statements” included below for additional information regarding forward-looking statements.

Forward-Looking Statements

This report contains, in addition to historical information, certain information, assumptions and discussions that may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated. Although we believe our assumptions underlying our forward-looking statements are reasonable as of the date of this report, we cannot assure you that the forward-looking statements set out in this report will prove to be accurate. We typically identify these forward-looking statements by the use of forward-looking words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or the negative version of those words or other comparable words. Forward-looking statements contained in this report include, but are not limited to, statements about:

	●	whether we can obtain approval from the U.S. Food and Drug Administration, or FDA, and foreign regulatory bodies, to commence our clinical studies and to sell, market and distribute our therapeutics and devices under development;

	●	our ability to successfully initiate and complete clinical trials of our pharmaceutical candidates under development, including our oral and topical Endoxifen (an active metabolite of Tamoxifen) and our intraductal technologies to administer therapeutics, including our study using fulvestrant;

	●	the success, cost and timing of our product and drug development activities and clinical trials, including whether the ongoing clinical study using our intraductal technologies to administer fulvestrant and our study using our oral Endoxifen in the window of opportunity prior to surgery will enroll a sufficient number of subjects or be completed in a timely fashion or at all;

	●	whether we will successfully complete our clinical study of topical Endoxifen to reduce mammographic breast density and whether the study will fail to achieve its objective, including because some participants have discontinued the study prior to completing the full six months of dosing because of skin irritation issues or for other reasons;

	●	our ability to contract with third-party suppliers, manufacturers and service providers, including clinical research organizations, and their ability to perform adequately;

	●	our ability to successfully develop and commercialize new therapeutics currently in development or that we might identify in the future and in the time frames currently expected;

	●	our ability to successfully defend litigation and other similar complaints that may be brought in the future, in a timely manner and within the coverage, scope and limits of our insurance policies;

	●	our ability to establish and maintain intellectual property rights covering our products;

	●	our expectations regarding, and our ability to satisfy, federal, state and foreign regulatory requirements;

	●	the accuracy of our estimates of the size and characteristics of the markets that our products and services may address;

	●	whether the final study results will vary from preliminary study results that we may announce;

	●	our expectations as to future financial performance, expense levels and capital sources;

	●	our ability to attract and retain key personnel; and

	●	our ability to raise capital.

These and other forward-looking statements made in this report are presented as of the date on which the statements are made. We have included important factors in the cautionary statements included in this report, particularly in the section titled “ITEM 1A. RISK FACTORS,” that we believe could cause actual results or events to differ materially from the anticipated results as set forth in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any new information, future events or circumstances that may affect our business after the date of this report. Except as required by law, we do not intend to update any forward-looking statements after the date on which the statement is made, whether as a result of new information, future events or circumstances or otherwise.

Company Overview

We are a clinical-stage biopharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. Our lead program is the development of Endoxifen, which is an active metabolite of tamoxifen, an FDA-approved drug to treat and prevent breast cancer. We are developing an oral and topical form of Endoxifen. Our Endoxifen is being developed to potentially treat a number of conditions, including: mammographic breast density (or, MBD); breast cancer in the “window of opportunity” between diagnosis of breast cancer and surgery; gynecomastia, which is male breast enlargement; and the recurrence of breast cancer in patients who do not benefit from taking tamoxifen meaning that they are “refractory” to tamoxifen. We are also developing our patented intraductal delivery technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies and Chimeric Antigen Receptor T-cell therapies (CAR-T therapies), directly to the site of breast cancer.

In 2017, we completed a Phase 1 placebo-controlled clinical study of our proprietary oral and topical formulations of Endoxifen in 48 healthy women. All objectives were met: there were no clinically significant safety signals and no clinically significant adverse events, and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels from daily doses of oral tamoxifen. In September 2018, we completed a Phase 1 placebo-controlled clinical study of our proprietary topical Endoxifen in 24 healthy men. All of our objectives of safety, tolerability and pharmacokinetics were successfully met.

We are currently conducting two Phase 2 studies of our proprietary Endoxifen: one in Stockholm, Sweden using our topical Endoxifen for reduction of MBD and another in Australia using our oral Endoxifen for patients in the window of opportunity between diagnosis of breast cancer and surgery. In October 2018, the MBD study in Sweden was fully-enrolled with all 90 participants: 60 participants on two different dose levels and 30 participants on placebo. Dosing in this study was completed in April 2019 and we expect to report preliminary results in the second quarter 2019.

In December 2018, we began providing our oral Endoxifen to a pre-menopausal, estrogen-receptor positive (ER+), lacking CYP2D6 function, breast cancer patient under an FDA-approved "expanded access" program. The purpose of this therapeutic approach was to reduce activity of the cancer cells prior to surgery. The patient received daily doses of our oral Endoxifen for approximately three weeks prior to surgery. There were no safety or tolerability issues and her surgery was successfully completed. The cancer cell biological activity was reduced, based on the estrogen receptor activity of the tumor cells and a 50% reduction in Ki-67. The FDA has also approved use of our Endoxifen for this patient following her surgery, under the FDA expanded access IND program, the use of our proprietary oral Endoxifen is restricted solely to this patient.

We are currently conducting a Phase 2 study at Montefiore Medical Center, Bronx, New York, using our intraductal technology to deliver fulvestrant directly to the site of the tumor via the breast ducts. Our program to use our intraductal technology to deliver CAR-T and other immunotherapies is in the pre-clinical phase.

Research and Development Phase

We are in the research and development phase and are not currently marketing any products or services. We do not anticipate generating revenue unless and until we develop and launch our pharmaceutical programs.

Commercial Lease Agreements

On November 1, 2018, the Company entered into an operating lease to pay $3,660 monthly rent for a term of 22 months with WW 107 Spring Street LLC to lease office space at 107 Spring Street, Seattle, Washington.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates.

Significant changes to our accounting policies as a result of adopting ASC Topic 842 are discussed in Note 11 of the notes to our unaudited condensed consolidated financial statements. There were no other changes in our significant accounting policies and estimates during the three months ended March 31, 2019, from those set forth in “Note 3, Summary of Accounting Policies” in our Annual Report on Form 10-K for the year ended December 31, 2018. We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.

Share-Based Payments

We follow the provisions of ASC 718, Compensation – Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense based on the grant date’s fair value was estimated in accordance with the provisions of ASC 718 and is recognized as an expense over the requisite service period with forfeitures recognized when they occur.

The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of our stock options, the expected life of the options, an expectation regarding future dividends on our common stock, and estimation of an appropriate risk-free interest rate. Our expected common stock price volatility assumption is based upon the volatility of our stock price. The expected life assumption for stock option grants was based upon the simplified method provided for under ASC 718-10, which averages the contractual term of the options of ten years with the average vesting term of one to four years. The dividend yield assumption of zero is based upon the fact that we have never paid cash dividends and presently have no intention of paying cash dividends in the future. The risk-free interest rate used for each grant was based upon prevailing short-term interest rates over the expected life of the options.

Results of Operations

Comparison of the three months ended March 31, 2019 and 2018

Revenue and Cost of Revenue: For the three months ended March 31, 2019 and 2018, we have no source of sustainable revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were approximately $4,064,000 for the three months ended March 31, 2019, which is an increase of approximately $2,190,000 or 117%, from the three months ended March 31, 2018. Operating expenses for 2019 consisted of research and development (R&D) expenses of approximately $1,451,000 and general and administrative (G&A) expenses of approximately $2,613,000. Operating expenses for 2018 consisted of R&D expenses of approximately $471,000, and G&A expenses of approximately $1,403,000.

Research and Development Expenses: R&D expenses for the three months ended March 31, 2019, were approximately $1,451,000, an increase of approximately $980,000 or 208% from total R&D expenses for the three months ended March 31, 2018 of approximately $471,000. The increase in R&D expense is attributed to salaries, stock-based compensation, and clinical trial expenses associated with our Endoxifen program. Stock-based compensation expense increased approximately $668,000 in 2019 resulting from the cancellation of stock options. There were no Liability Option cancellations in the comparable period in 2018. We expect our R&D expenses to increase throughout 2019 as we commence additional Phase 2 clinical studies of Endoxifen, continue the clinical trial of Fulvestrant administered via our intraductal technology and continue the development of other indications and therapeutics, including CAR-T and immunotherapies administered via our intraductal technologies.

General and Administrative Expenses: G&A expenses were approximately $2,613,000 for the three months ended March 31, 2019, an increase of approximately $1,210,000, or 86% from the total G&A expenses for the three months ended March 31, 2018, of approximately $1,403,000. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The increase in G&A expenses for the quarter ended March 31, 2019, is mainly attributed to an increase in stock-based compensation expense due to the cancellation of the 2018 Liability Options of approximately $1,074,000, payroll expenses resulting from salary increases, and increased legal and professional consulting expenses over the prior year.

Income taxes: We have incurred net operating losses from inception; we did not record an income tax benefit for our incurred losses for the three months ended March 31, 2019 and 2018, due to uncertainty regarding utilization of our net operating carryforwards and due to our history of losses.

Liquidity and Capital Resources

Cash Flows

As of March 31, 2019, we had cash, cash equivalents and restricted cash of approximately $19.7 million.

Net Cash Flows from Operating Activities: Net cash used in operating activities was approximately $2,149,000 for the three months ended March 31, 2019, a decrease of approximately $238,000, or 10%, compared to net cash used in operating activities for the three months ended March 31, 2018 of approximately $2,387,000. The decrease in the 2019 period as compared to 2018 resulted primarily from decreased spending on R&D activities.

Net Cash Flows from Financing Activities: Net cash provided by financing activities was approximately $11,337,000 for the three months ended March 31, 2019, which represents proceeds from the exercise of warrants issued in the May 2018 financing. There were no comparable warrant exercises or financing activities for the three months ended March 31, 2018.

Funding Requirements

We expect to incur ongoing operating losses for the foreseeable future as we continue to develop our planned therapeutic programs including related clinical studies and other programs in the pipeline. We expect that our current available funding will be sufficient to fund our planned operations for at least the next 12 to 18 months from the date of this report. If we meet certain requirements, we may sell securities that are registered on our Form S-3 registration statement, and by raising capital through sales of securities to third parties and existing stockholders. If we are unable to raise additional capital when needed, however, we could be forced to curtail or cease operations. Our future capital uses and requirements will depend on the time and expenses needed to begin and continue clinical trials for our new drug developments.

Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities or by selling debt securities, if convertible, further dilution to our existing stockholders would result. To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements.

If adequate funds are not available, we may be required to terminate, significantly modify or delay our development programs, reduce our planned commercialization efforts, or obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. Further, we may elect to raise additional funds even before we need them if we believe the conditions for raising capital are favorable.

Off-Balance Sheet Arrangements

We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts.

Recently Adopted Accounting Pronouncements:

Recent Accounting Pronouncements:

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2019. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer concluded that, as of March 31, 2019, the Company’s disclosure controls and procedures were not effective at the reasonable assurance level.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended March 31, 2019, that has materially affected, or is reasonably likely to materially affect our disclosure controls and procedures

For the quarter ended June 30, 2018, we identified a material weakness in the internal controls over the calculation of the deemed dividend on Series B convertible preferred stock (the “deemed dividend”) for the three and six months June 30, 2018. Because of this error, an incorrect deemed dividend was included in net loss applicable to common stockholders which caused an incorrect calculation of loss per common share, basic and diluted. Management misinterpreted the technical guidance contained in ASC 470- Debt in calculating the deemed dividend. An appropriately detailed knowledge of ASC 470 -Debt was not present to prevent or detect this error. We incorrectly stated the amount of the deemed dividend as $4,782,100, rather than $11,479,308, for the three and six months ended June 30, 2018. We also incorrectly stated the loss per common share - basic and diluted, for the three and six months ended June 30, 2018 as $(2.90) and $(3.77) respectively, rather than the correct amount of $(5.08) and $(6.11), respectively. The condensed consolidated financial statements for the three and six months period ended June 30, 3018 were restated to correct the error.

Management’s remediation plan is to enhance the procedures performed to independently review technical accounting memorandums for accuracy and completeness including when appropriate with an outside independent accounting firm in future periods.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Litigation and Contingencies

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors described in our Annual Report on Form 10-K, as filed with the SEC on March 25, 2019.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

(a)

Exhibits

		Incorporated by Reference Herein
Exhibit No.	Description	Form	Date

4.1	Form of 2019 Option Award Agreement	Current Report on Form 8-K, as Exhibit 4.1	January 15, 2019
4.2	2010 Stock Option and Incentive Plan, as amended January 13, 2019	Current Report on Form 8K, as Exhibit 4.2	January 15, 2019
31.1	Certification pursuant to Rule 13a-14(a) under the securities Exchange Act of 1934 of Steven C. Quay	Filed herewith
31.2	Certification pursuant to Rule 13a-14(a) under the securities Exchange Act of 1934 of Kyle Guse	Filed herewith
32.1	Certification pursuant to 18 U.S.C. Section 1350 of Steven C. Quay	Filed herewith
32.2	Certification pursuant to 18 U.S.C. Section 1350 of Kyle Guse	Filed herewith

101	Interactive Data Files pursuant to Rule 405 of Regulation S-T	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 13, 2019

/s/ Steven C. Quay
President and Chief Executive Officer
(On behalf of the Registrant)

/s/ Kyle Guse
Kyle Guse
Chief Financial Officer, General Counsel and Secretary
(As Principal Financial and Accounting Officer)

EX-31.1 2 ex_141347.htm EXHIBIT 31.1 ex_141347.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven C. Quay, certify that:

1. I have reviewed this Quarterly Report of Atossa Genetics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, statements of stockholders' equity and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date: May 13, 2019

	/s/ Steven C. Quay
	Steven C. Quay
	Chief Executive Officer and President
	(Principal executive officer)

EX-31.2 3 ex_141348.htm EXHIBIT 31.2 ex_141348.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kyle Guse, certify that:

1. I have reviewed this Quarterly Report of Atossa Genetics Inc.;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, statement of stockholders' equity and cash flows of the registrant as of, and for, the periods presented in this report;

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date: May 13, 2019

	/s/Kyle Guse
	Kyle Guse
	Chief Financial Officer, General Counsel and Secretary
	(Principal financial and accounting officer)

EX-32.1 4 ex_141349.htm EXHIBIT 32.1 ex_141349.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atossa Genetics Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven C. Quay, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Date: May 13, 2019

	/s/ Steven C. Quay
	Steven C. Quay
	Chief Executive Officer and President
	(Principal executive officer)

EX-32.2 5 ex_141350.htm EXHIBIT 32.2 ex_141350.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atossa Genetics Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kyle Guse, Chief Financial Officer, General Counsel and Secretary of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Date: May 13, 2019

	/s/ Kyle Guse
	Kyle Guse
	Chief Financial Officer, General Counsel and Secretary
	(Principal financial and accounting officer)

EX-101.INS 6 atos-20190331.xml XBRL INSTANCE DOCUMENT 3151944 3151944 3151944 19852 19852 2800000 35000 38000 -280242 37595 185000000 13624 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4:</div> PREPAID EXPENSES</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Prepaid expenses consisted of the following:</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">234,875</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160,576</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">392,894</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">218,090</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Professional services</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110,094</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Financial exchange fees</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">58,685</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid rent</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Retainer and security deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,218</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,718</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,446</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,355</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total prepaid expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">835,468</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">509,833</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div></div> 58685 12300000 96250 110094 3151944 0.435 392894 218090 238000 203000 237856 518098 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5:</div> RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 23, 2017, </div>Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> and Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> Endoxifen clinical trials. Australia offers an R&D cash rebate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.435</div> per dollar spent on qualified R&D activities incurred in the country. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company incurred qualified R&D expenses of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$80,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$86,000,</div> respectively. The Company recorded a rebate receivable of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$35,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$38,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively and a corresponding credit to R&D expenses. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>we had a total R&D rebate receivable of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$238,000</div> that includes approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$203,000</div> receivable remaining from the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018. </div></div></div> 2502 2871 4128 5463 7257 12623 106076 233862 374782 P10Y 2800000 2799188 503854 10832856 11336710 19300000 false --12-31 Q1 2019 2019-03-31 10-Q 0001488039 9124732 Yes false Non-accelerated Filer ATOSSA GENETICS INC true atos

463970

353328

646433

697995

74844

177074

82706

76335

162619

160740

98056781

82204902

701999

2378997

215139

275833

215139

1741919

224676

166701

51157

48438

275833

215139

1074183

667736

783383

14473

458994

3369468

76235

4611845

90708

21024728

11720446

20779528

11549366

19568247

4779519

10380493

10490493

7272469

19678247

4834519

9187754

-2437950

18925000

10052000

4.05

3869216

1070028

0.18

175000000

9122171

5846552

9122171

5846552

1641979

1052372

1677

476431

284

1410025

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">234,875</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160,576</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">392,894</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">218,090</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Professional services</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110,094</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Financial exchange fees</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">58,685</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid rent</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Retainer and security deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,218</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,718</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,446</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,355</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total prepaid expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">835,468</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">509,833</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

14218

16718

13983

7864

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12:</div> STOCK BASED COMPENSATION</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Stock Option and Incentive Plan</div></div> <div style=" margin: 0pt 7.5pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 28, 2010, </div>the Board of Directors approved the adoption of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Stock Option and Incentive Plan the (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2010</div> Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2020. </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> other awards <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan after the date that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> years from the date of stockholder approval. An aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,556</div> shares were initially reserved for issuance in connection with awards granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan and on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 18, 2016, </div>an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,111</div> shares were reserved for issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2018, </div>the stockholders approved an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,000</div> shares for issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 12, 2018, </div>the stockholders approved an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500,000</div> shares for issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan.</div> <div style=" margin: 0pt; text-align: justify; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The following table presents the automatic additions to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan since inception pursuant to the “evergreen” terms of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan:</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 85%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">January 1,</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of<br /> shares</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2012</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,502</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2013</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,871</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2014</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,128</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2015</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,463</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2016</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,257</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,623</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106,076</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">233,862</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total additional shares</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">374,782</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt 7.5pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div></div> grant options to purchase shares of common stock during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div></div> options were exercised during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> There are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">236,430</div> shares available for grant under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$275,833</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$215,139</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively (excluding the liability options discussed below).</div> <div style=" margin: 0pt 14.4pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 14.4pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended March 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,676</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">166,701</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">51,157</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,438</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total stock compensation Expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">275,833</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">215,139</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Options issued and outstanding as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan and their activities during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months then ended are as follows:</div> <div style=" margin: 0pt 7.5pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of<br /> Underlying<br /> Shares</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Exercise Price<br /> Per Share</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Contractual<br /> Life Remaining<br /> in Years</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate<br /> Intrinsic Value</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 52%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of January 1, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,383</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.14</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,383</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.14</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.92</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">695,400</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable as of March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">434,515</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19.38</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.84</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">374,063</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,383</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.14</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.92</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">695,400</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt 7.5pt; text-align: justify; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: justify; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">348,868</div> unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$876,533.</div> This expense is expected to be recognized over a weighted-average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.40</div> years.</div> <div style=" margin: 0pt; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">  </div> <div style=" margin: 0pt 0pt 0pt -27pt; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Liability Options</div></div> <div style=" margin: 0pt; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 27, 2018, </div>the Company granted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300,000</div> options to the Chief Executive Officer (CEO) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">700,000</div> to the Chief Financial Officer (CFO) (the "Liability Options"). Each option was exercisable for an equivalent number of shares of Company's common stock. The Liability Options were granted pursuant to an option award agreement and were granted outside the Company’s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan; however, they were subject to the terms and conditions of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>the Liability Options were canceled.</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Liability Options were exercisable for shares of common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.38</div> per share, which was the fair value on the date of grant. The options had an exercise period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years from their date of issuance. If at the time the options were exercised the Company could <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> deliver shares of common stock to the optionee including, for example, if there were insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option only would be exercised on a cash “net basis” so that the Company would pay cash in an amount equal to the excess of the fair value of the common stock over the option exercise price. If there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> sufficient shares available under the Plan, the Company would have been obligated to settle these options in cash if they were exercised. Because these options contained provisions that would require the Company to settle the options in cash in an event outside the Company’s control, they were accounted for as liabilities.</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The Liability Options were subject to vesting requirements. Twenty-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> percent of the options were vested as of the grant date, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the options would have vested quarterly over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years, and the remaining <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> would have vested upon achievement of certain milestones related to clinical trial progress. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>all of the Liability Options that vested upon achievement of clinical trial milestones were vested. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>the Liability Options were cancelled and at the time of cancellation, there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,125,000</div> unvested Liability Options outstanding.</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Compensation costs associated with the Liability Options were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement.</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">  </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">At the time of cancellation, the fair value of Liability Options at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>was calculated using the Black-Scholes option-pricing model applying the following assumptions:</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">January 13,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.53</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.50-5.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock price</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.36</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 12%; text-align: right;"> </td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">121.0-123.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;">%</div> </td> </tr> </table> </div> <div style=" margin: 0pt 14.7pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">As a result of the cancellation, the Company recognized all remaining unrecognized compensation expense related to these options of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,741,919,</div> which was included in the following captions in the condensed consolidated statements of operations: </div> <div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Period Ended March 31, 2019</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,074,183</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">667,736</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total stock compensation expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,741,919</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt 14.7pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Also on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>at the same time the Liability Options were cancelled, the Company awarded a new option to the CEO to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,300,000</div> shares of Common Stock and a new option to the CFO to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">800,000</div> shares of common stock (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2019</div> Options”). The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options: (i) have an exercise price equal to the fair market value of Common Stock on the date of board of director approval which was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.36</div> per share, (ii) do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> contain a net cash exercise provision, (iii) are awarded pursuant to the terms and conditions of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan as amended by the Board of Directors on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>to include shares issuable upon exercise of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options and other changes to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan so that the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> conflict with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Plan (the “Amended Plan”), (iv) vest and are exercisable in accordance with the vesting schedule related to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Liability Options; provided, however, that the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> exercisable unless and until the Company’s stockholders approve the Amended Plan to increase the authorized number of shares available for grant under the Plan and (vi) are subject to and conditioned upon the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Option Agreements with the optionees and the employment agreements with the optionees.</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The above actions were unanimously approved by the disinterested members of the Board of Directors. The above actions are intended to eliminate the Company’s potential liability associated with the net cash exercise provision of the liability options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options.</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 0pt 0pt -27pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Accounting treatment</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Awards offered under a plan that are subject to shareholder approval are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> considered granted under GAAP until the approval is obtained, unless such approval is essentially a formality (or perfunctory). For example, if management and board members control sufficient votes to approve the plan, the vote <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be considered perfunctory. As management and the Company’s Board of Directors do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> control enough votes to approve the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options, the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> deemed granted under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718.</div> Cancellation of an award that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> accompanied by the concurrent grant are accounted for as a repurchase for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> consideration. Accordingly, any previously unrecognized compensation cost is recognized at the cancellation date. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 13, 2019, </div>as noted above, the Company recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,741,919</div> of unrecognized compensation cost related to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Liability Options. Additionally, the fair value of the stock-based compensation liability of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,151,944</div> was reclassified to additional-paid in capital on the cancellation date. If shareholder approval is obtained and a grant date is established for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> Options, the Company will measure and record them as a new grant under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718.</div></div> <div style=" margin: 0pt 0pt 0pt 7.2pt; text-align: left; text-indent: 28.8pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div></div>

-0.62

-8.48

891758

935070

P1Y146D

876533

91667

99375

2613093

1403465

1741919

-4073307

-1874382

110642

-166554

-102230

82508

-43312

-428440

-2985

-51512

-30076

7789

325635

244723

12000

44000

12000

1528538

2915436

21024728

11720446

1491141

2915436

11336710

-51068

-2148956

-2386882

-4073307

-1874382

-4073307

-1874382

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Pronouncements:</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">In the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> we adopted Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-style: italic;">Lease Accounting</div> Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div><div style="display: inline; font-style: italic;">: ("</div>Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div><div style="display: inline; font-style: italic;">")</div> and recognized on our Condensed Consolidated Balance Sheet <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$101,000</div> of lease liabilities with corresponding right-of-use assets for operating leases. The new lease standard requires a lessee to measure its operating lease liabilities at the present value of the remaining minimum lease payments with a discounted cash flow model using the interest rate implicit in the lease. If the implicit interest rate cannot be readily determined, the lessee must use its incremental borrowing rate (“IBR”). If the lessee does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have an IBR, the lessee must use a rate that approximates the rate of interest that the lessee would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. The implicit interest rate was readily determinable for our copier lease; however, we used an IBR to measure our adoption date operating lease liability related to our office space which rate represents our estimated borrowing rate on a secured loan collateralized by similar assets for a similar term. The adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have an impact on the Condensed Consolidated Statements of Cash Flows. As permitted under the standard, we elected prospective application of the new guidance and prior periods continue to be presented in accordance with Accounting Standards Codification ("ASC") Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840.</div> Refer to our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for disclosures required by Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840.</div> The new standard provides a number of optional practical expedients in transition. We elected the practical expedients to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reassess its prior conclusions about lease identification under the new standard, to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reassess lease classification, and to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reassess initial direct costs. We did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> elect the practical expedient allowing the use-of-hindsight which would require us to reassess the lease term of its leases based on all facts and circumstances through the effective date and did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> elect the practical expedient pertaining to land easements as this is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> applicable to our current contract portfolio. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic;">Commitments and Contingencies,</div> of the notes to our unaudited condensed consolidated financial statements for additional discussion of our leases and the amounts recognized in these unaudited condensed consolidated financial statements.</div> <div style=" margin: 0pt; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019, </div>we adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">08,</div> <div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Not</div>-for-Profit Entities (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">958</div>): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.</div> This ASU affects <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div>-for-profit entities and business entities that receive or make contributions of cash. The ASU clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">958</div> or as an exchange transaction subject to other guidance. The adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any impact on the financial statements.</div> <div style=" margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 14.4pt; text-align: left; text-indent: -18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements:</div> </div> <div style=" margin: 0pt 14.4pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 7.2pt 0pt -2pt; text-align: justify; text-indent: 27pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> <div style="display: inline; font-style: italic;">Fair Value Measurement (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">820</div>): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement</div>, to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">820,</div> “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2019. </div>Early adoption is permitted, including adoption in an interim period. Furthermore, an entity is permitted to early adopt any removed or modified disclosures upon issuance of the update and delay adoption of the additional disclosures until their effective date. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect this amendment to have a material impact on our consolidated financial statements.</div></div></div></div>

4064329

1874441

-4064329

-1874441

12900

101000

50706

37397

14600

101000

88103

0.12

P1Y255D

27957

30942

17218

9863

39939

-8978

21446

4355

51068

0.001

10000000

750000

4000

25000

10000000

702

2379

702

2379

835468

509833

234875

160576

17100

11336710

48212

54487

80000

86000

1451236

470976

110000

55000

110000

-80904570

-76831263

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of<br /> Underlying<br /> Shares</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Exercise Price<br /> Per Share</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Contractual<br /> Life Remaining<br /> in Years</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate<br /> Intrinsic Value</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 52%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of January 1, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,383</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.14</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,383</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.14</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.92</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">695,400</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable as of March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">434,515</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19.38</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.84</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">374,063</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,383</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.14</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.92</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">695,400</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

P2Y

0.0253

11111

125000

500000

5556

236430

434515

19.38

2300000

700000

2300000

800000

695400

783383

12.14

695400

783383

12.14

2.38

1.36

0.25

0.5

0.25

P10Y

374063

P8Y306D

348868

1125000

P8Y335D

220996

2379

5846552

702

9122171

476431

13624

-1676998

85753

1591246

275833

215139

19496190

8805010

477342

71887674

-65426329

6938687

477342

72082961

-67300711

5259592

2378997

1052372

82204902

-76831263

701999

1641979

98056781

-80904570

6565514

220996

xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2010-09-28 2010-09-28 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2012-01-01 2012-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2012-01-01 2019-03-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2013-01-01 2013-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2014-01-01 2014-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2015-01-01 2015-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2016-01-01 2016-12-31 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2016-05-18 2016-05-18 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2017-01-01 2017-12-31 0001488039 2018-01-01 2018-03-31 0001488039 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember 2018-01-01 2018-03-31 0001488039 us-gaap:WarrantMember 2018-01-01 2018-03-31 0001488039 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001488039 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001488039 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2018-01-01 2018-03-31 0001488039 atos:AtossaGeneticsAUSPtyLtdMember 2018-01-01 2018-03-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2018-01-01 2018-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember atos:PreferredStockAdditionalPaidinCapitalMember 2018-01-01 2018-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001488039 atos:CommonStockAdditionalPaidinCapitalMember 2018-01-01 2018-03-31 0001488039 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001488039 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2018-01-01 2018-12-31 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2018-04-12 2018-04-12 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2018-05-09 2018-05-09 0001488039 atos:SeriesBConvertiblePreferredStockMember atos:The2018SubscriptionRightsOfferingMember 2018-05-30 2018-05-30 0001488039 atos:The2018SubscriptionRightsOfferingMember 2018-05-30 2018-05-30 0001488039 atos:LiabilityOptionsMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember srt:ChiefExecutiveOfficerMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember srt:ChiefFinancialOfficerMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-06-27 2018-06-27 0001488039 atos:LiabilityOptionsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-06-27 2018-06-27 0001488039 2019-01-01 2019-03-31 0001488039 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001488039 us-gaap:WarrantMember 2019-01-01 2019-03-31 0001488039 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001488039 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001488039 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2019-01-01 2019-03-31 0001488039 atos:LiabilityOptionsMember 2019-01-01 2019-03-31 0001488039 atos:AtossaGeneticsAUSPtyLtdMember 2019-01-01 2019-03-31 0001488039 atos:ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember 2019-01-01 2019-03-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2019-01-01 2019-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember atos:PreferredStockAdditionalPaidinCapitalMember 2019-01-01 2019-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001488039 atos:CommonStockAdditionalPaidinCapitalMember 2019-01-01 2019-03-31 0001488039 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001488039 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001488039 2019-01-13 2019-01-13 0001488039 atos:LiabilityOptionsMember 2019-01-13 2019-01-13 0001488039 atos:LiabilityOptionsMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-13 2019-01-13 0001488039 atos:LiabilityOptionsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-13 2019-01-13 0001488039 atos:The2019OptionsMember 2019-01-13 2019-01-13 0001488039 atos:The2019OptionsMember srt:ChiefExecutiveOfficerMember 2019-01-13 2019-01-13 0001488039 atos:The2019OptionsMember srt:ChiefFinancialOfficerMember 2019-01-13 2019-01-13 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2010-09-28 0001488039 atos:AtossaGeneticsAUSPtyLtdMember 2017-05-23 0001488039 2017-12-31 0001488039 atos:SeriesBConvertiblePreferredStockMember atos:PreferredStockAdditionalPaidinCapitalMember 2017-12-31 0001488039 atos:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2017-12-31 0001488039 atos:CommonStockAdditionalPaidinCapitalMember 2017-12-31 0001488039 us-gaap:CommonStockMember 2017-12-31 0001488039 us-gaap:RetainedEarningsMember 2017-12-31 0001488039 2018-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember atos:PreferredStockAdditionalPaidinCapitalMember 2018-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2018-03-31 0001488039 atos:CommonStockAdditionalPaidinCapitalMember 2018-03-31 0001488039 us-gaap:CommonStockMember 2018-03-31 0001488039 us-gaap:RetainedEarningsMember 2018-03-31 0001488039 atos:The2018WarrantsMember atos:The2018SubscriptionRightsOfferingMember 2018-05-30 0001488039 2018-12-31 0001488039 atos:AtossaGeneticsAUSPtyLtdMember 2018-12-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2018-12-31 0001488039 atos:SeriesBConvertiblePreferredStockMember atos:PreferredStockAdditionalPaidinCapitalMember 2018-12-31 0001488039 atos:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001488039 atos:CommonStockAdditionalPaidinCapitalMember 2018-12-31 0001488039 us-gaap:CommonStockMember 2018-12-31 0001488039 us-gaap:RetainedEarningsMember 2018-12-31 0001488039 2019-01-01 0001488039 atos:LiabilityOptionsMember 2019-01-13 0001488039 2019-03-31 0001488039 us-gaap:EmployeeStockOptionMember atos:The2010StockOptionAndIncentivePlanMember 2019-03-31 0001488039 atos:AtossaGeneticsAUSPtyLtdMember 2019-03-31 0001488039 atos:ConversionOfSeriesBConvertiblePreferredStockIntoCommonStockMember 2019-03-31 0001488039 atos:The2010StockOptionAndIncentivePlanMember 2019-03-31 0001488039 atos:SeriesAConvertiblePreferredStockMember 2019-03-31 0001488039 atos:SeriesAJuniorParticipatingPreferredStockMember 2019-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember 2019-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember atos:PreferredStockAdditionalPaidinCapitalMember 2019-03-31 0001488039 atos:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-03-31 0001488039 atos:CommonStockAdditionalPaidinCapitalMember 2019-03-31 0001488039 us-gaap:CommonStockMember 2019-03-31 0001488039 us-gaap:RetainedEarningsMember 2019-03-31 0001488039 2019-05-09

EX-101.SCH 7 atos-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudied) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Operations link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Liquidity and Capital Resources link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Summary of Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Prepaid Expenses link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Research and Development Tax Rebate Receivable link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Payroll Liabilities link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Concentration of Credit Risk link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Stock Based Compensation link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 4 - Prepaid Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 6 - Payroll Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 12 - Stock Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 2 - Liquidity and Capital Resources (Details Textual) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 3 - Summary of Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 5 - Research and Development Tax Rebate Receivable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 9 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 10 - Concentration of Credit Risk (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 12 - Stock Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 12 - Stock Based Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 12 - Stock Based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 12 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 atos-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 atos-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 atos-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield Note To Financial Statement Details Textual Significant Accounting Policies us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, Payments, Due Year Two Note 4 - Prepaid Expenses Note 6 - Payroll Liabilities Risk free interest rate Note 8 - Net Loss Per Share Note 12 - Stock Based Compensation Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) Long term liabilities Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) Income Tax Disclosure [Text Block] Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) Compensation cost for stock options granted us-gaap_StockOptionPlanExpense Note 12 - Stock Based Compensation - Stock-based Compensation Expense (Details) Note 12 - Stock Based Compensation - Stock Option Activity (Details) Other assets Note 12 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details) us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year us-gaap_LiabilitiesCurrent Total current liabilities Notes To Financial Statements Notes To Financial Statements [Abstract] Other current liabilities Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Operating expenses Share-based Payment Arrangement, Option, Activity [Table Text Block] us-gaap_ConversionOfStockAmountConverted1 Conversion of Series B convertible preferred stock to common stock us-gaap_ConversionOfStockSharesIssued1 Conversion of Stock, Shares Issued Depreciation and amortization Stock-based compensation liability Vested and expected to vest, weighted average contractual life remaining in years (Year) us-gaap_ConversionOfStockSharesConverted1 Conversion of Stock, Shares Converted Conversion of Series B convertible preferred stock to common stock (in shares) Vested and expected to vest, shares (in shares) Stock Conversion Description [Axis] Vested and expected to vest, Weighted average exercise price per share (in dollars per share) Conversion of Stock, Name [Domain] Vested and expected to vest, aggreate instrinsic value Exercisable, Weighted average exercise price per share (in dollars per share) us-gaap_AssetsCurrent Total current assets Exercisable, weighted average contractual life remaining in years (Year) Exercisable, aggreate instrinsic value Stockholders' Equity Note Disclosure [Text Block] Exercisable, shares (in shares) Outstanding, weighted average contractual life remaining in years (Year) Outstanding, aggreate instrinsic value Change in fair value of stock-based compensation liability Common stock - $0.18 par value; 175,000,000 shares authorized, and 9,122,171 and 5,846,552 shares issued and outstanding, as of March 31, 2019 and December 31, 2018, respectively us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance Adjustments to reconcile net loss to net cash used in operating activities us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, Weighted average exercise price per share (in dollars per share) Outstanding, Weighted average exercise price per share (in dollars per share) Common stock, authorized (in shares) Common Stock, Shares Authorized Common stock, issued (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accrued expenses Payroll liabilities Total payroll liabilities us-gaap_OperatingLeasePayments Operating Lease, Payments Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding, shares (in shares) Outstanding, shares (in shares) Other current assets Accrued bonuses Preferred stock - $0.001 par value; 10,000,000 shares authorized; 702 and 2,379 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively Preferred stock, issued (in shares) Preferred Stock, Shares Issued, Total Accrued payroll Other us-gaap_PolicyTextBlockAbstract Accounting Policies Accrued vacation Prepaid expenses Total prepaid expenses Prepaid rent Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Prepaid insurance us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of furniture and equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized NONCASH INVESTING AND FINANCING ACTIVITIES us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Additional paid-in capital- Series B convertible preferred stock us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-based Payment Arrangement, Tranche Three [Member] Current liabilities Vesting [Axis] Vesting [Domain] Share-based Payment Arrangement, Tranche One [Member] Share-based Payment Arrangement, Tranche Two [Member] us-gaap_Assets Total Assets Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount us-gaap_OperatingLeaseExpense Operating Lease, Expense CASH FLOWS FROM OPERATING ACTIVITIES us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net loss attributable to common shareholders us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Statement [Line Items] Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Additional paid-in capital Stockholders' equity Other income (expense) Award Type [Domain] Chief Financial Officer [Member] Chief Executive Officer [Member] us-gaap_RestrictedCashAndCashEquivalents Restricted cash Current assets Net loss Net Income (Loss) Attributable to Parent, Total Net loss Basis of Presentation and Significant Accounting Policies [Text Block] Award Type [Axis] Intangible assets, net us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE Retainer and security deposits us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities us-gaap_Liabilities Total Liabilities Commitments and contingencies (note 11) Sale of Stock [Axis] Sale of Stock [Domain] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Operating loss us-gaap_NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Share-based Payment Arrangement, Option [Member] us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Commitments and Contingencies Disclosure [Text Block] Furniture and equipment, net Consolidated Entities [Axis] Consolidated Entities [Domain] atos_ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation Reclassification of stock-based liability awards to equity upon cancellation The amount of stock-based liability awards reclassified to equity upon cancellation. CASH FLOWS FROM INVESTING ACTIVITY Proceeds from exercise of warrants Proceeds from Warrant Exercises Retained Earnings [Member] Earnings Per Share [Text Block] Title of Individual [Domain] Title of Individual [Axis] us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Payroll liabilities Common Stock [Member] Preferred Stock [Member] Income taxes Income Tax Expense (Benefit), Total us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses Equity Components [Axis] Equity Component [Domain] us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income taxes Series A Convertible Preferred Stock [Member] Represents information about series A convertible preferred stock. us-gaap_OperatingExpenses Total operating expenses atos_ProceedsFromIssuanceOfStockUnits Proceeds from Issuance of Stock units The cash inflow from issuance of stock units. Series B Convertible Preferred Stock [Member] Represents information about series B convertible preferred stock. General and administrative Amortization of commitment shares Amortization of commitment shares It represents value of amortization of commitment shares. Restricted cash atos_WorkingCapital Working Capital Represents the value of total net current assets after deducting net current liabilities as of the balance sheet date. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and cash equivalents Conversion of Series B Convertible Preferred Stock into Common Stock [Member] Represents conversion of Series B Convertible Preferred Stock into common stock shares. us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other current liabilities Total stock compensation expense us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense Prepaid Expenses [Text Block] The entire disclosure related to prepaid expenses. Amendment Flag General and Administrative Expense [Member] Accounting Policies [Abstract] Basis of Accounting, Policy [Policy Text Block] The 2019 Options [Member[ Options granted to executive officers. Use of Estimates, Policy [Policy Text Block] Research and Development Tax Rebate Receivable [Text Block] Disclosure related to research and development tax rebate receivable. New Accounting Pronouncements, Policy [Policy Text Block] Concentration Risk Disclosure [Text Block] Prepaid research and development Amount of asset related to consideration paid in advance for research and development costs that provide benefits within a future period of one year or the normal operating cycle, if longer. Professional services Amount of asset related to consideration paid in advance for professional services costs that provide benefits within a future period of one year or the normal operating cycle, if longer. Liability Options [Member] Represents information about liability options. The 2010 Stock Option and Incentive Plan [Member] Represents information about the 2010 stock option and incentive plan. us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, outstanding (in shares) Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding, Ending Balance The 2018 Warrants [Member] Represents information about the 2018 warrants. Current Fiscal Year End Date Series A Junior Participating Preferred Stock [Member] Represents information about series A junior participating preferred stock. EX-101.PRE 11 atos-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2019	May 09, 2019
Document Information [Line Items]
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Trading Symbol	atos
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		9,124,732
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 19,568,247	$ 10,380,493
Restricted cash	110,000	110,000
Prepaid expenses	835,468	509,833
Research and development tax rebate receivable	237,856	518,098
Other current assets	27,957	30,942
Total current assets	20,779,528	11,549,366
Furniture and equipment, net	48,212	54,487
Intangible assets, net	91,667	99,375
Right-of-use asset	88,103
Other assets	17,218	17,218
Total Assets	21,024,728	11,720,446
Current liabilities
Accounts payable	463,970	353,328
Accrued expenses	74,844	177,074
Payroll liabilities	891,758	935,070
Stock-based compensation liability		1,410,025
Lease liability	50,706
Other current liabilities	9,863	39,939
Total current liabilities	1,491,141	2,915,436
Long term liabilities
Lease liability long term	37,397
Total Liabilities	1,528,538	2,915,436
Commitments and contingencies (note 11)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized; 702 and 2,379 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	1	2
Additional paid-in capital- Series B convertible preferred stock	701,999	2,378,997
Common stock - $0.18 par value; 175,000,000 shares authorized, and 9,122,171 and 5,846,552 shares issued and outstanding, as of March 31, 2019 and December 31, 2018, respectively	1,641,979	1,052,372
Additional paid-in capital	98,056,781	82,204,902
Accumulated deficit	(80,904,570)	(76,831,263)
Total Stockholders' Equity	19,496,190	8,805,010
Total Liabilities and Stockholders' Equity	$ 21,024,728	$ 11,720,446

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	702	2,379
Preferred stock, outstanding (in shares)	702	2,379
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	9,122,171	5,846,552
Common stock, outstanding (in shares)	9,122,171	5,846,552

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating expenses
Research and development	$ 1,451,236	$ 470,976
General and administrative	2,613,093	1,403,465
Total operating expenses	4,064,329	1,874,441
Operating loss	(4,064,329)	(1,874,441)
Other income (expense)	(8,978)	59
Loss before income taxes	(4,073,307)	(1,874,382)
Income taxes	0	0
Net loss	$ (4,073,307)	$ (1,874,382)
Loss per common share - basic and diluted (in dollars per share)	$ (0.62)	$ (8.48)
Weighted average shares outstanding - basic and diluted (in shares)	6,565,514	220,996

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017			220,996
Balance at Dec. 31, 2017			$ 477,342	$ 71,887,674	$ (65,426,329)	$ 6,938,687
Amortization of commitment shares				(19,852)		(19,852)
Compensation cost for stock options granted				215,139		215,139
Net loss					(1,874,382)	(1,874,382)
Balance (in shares) at Mar. 31, 2018			220,996
Balance at Mar. 31, 2018			$ 477,342	72,082,961	(67,300,711)	5,259,592
Balance (in shares) at Dec. 31, 2018	2,379		5,846,552
Balance at Dec. 31, 2018	$ 2	2,378,997	$ 1,052,372	82,204,902	(76,831,263)	8,805,010
Amortization of commitment shares
Compensation cost for stock options granted				275,833		275,833
Net loss					(4,073,307)	$ (4,073,307)
Issuance of common stock upon warrant exercise (in shares)			2,799,188			2,800,000
Issuance of common stock upon warrant exercise			$ 503,854	10,832,856		$ 11,336,710
Conversion of Series B convertible preferred stock to common stock (in shares)	(1,677)
Conversion of Series B convertible preferred stock to common stock	$ (1)
Conversion of Series B convertible preferred stock to common stock		(1,676,998)	$ 85,753	1,591,246
Conversion of Series B convertible preferred stock to common stock (in shares)			476,431
Reclassification of stock-based liability awards to equity upon cancellation				3,151,944		3,151,944
Balance (in shares) at Mar. 31, 2019	702		9,122,171
Balance at Mar. 31, 2019	$ 1	$ 701,999	$ 1,641,979	$ 98,056,781	$ (80,904,570)	$ 19,496,190

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudied) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,073,307)	$ (1,874,382)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted	275,833	215,139
Depreciation and amortization	13,983	7,864
Change in fair value of stock-based compensation liability	1,741,919
Changes in operating assets and liabilities:
Prepaid expenses	(325,635)	(244,723)
Research and development tax rebate receivable	280,242	(37,595)
Other assets	2,985	51,512
Accounts payable	110,642	(166,554)
Payroll liabilities	(43,312)	(428,440)
Accrued expenses	(102,230)	82,508
Other current liabilities	(30,076)	7,789
Net cash used in operating activities	(2,148,956)	(2,386,882)
CASH FLOWS FROM INVESTING ACTIVITY
Purchase of furniture and equipment		(51,068)
Net cash used in investing activities		(51,068)
CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from exercise of warrants	11,336,710
Net cash provided by financing activities	11,336,710
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	9,187,754	(2,437,950)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	10,490,493	7,272,469
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	19,678,247	4,834,519
SUPPLEMENTAL DISCLOSURES
Cash and cash equivalents	19,568,247	4,779,519
Restricted cash	110,000	55,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	19,678,247	4,834,519
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of stock-based liability awards to equity upon cancellation	3,151,944
Amortization of commitment shares		$ 19,852

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Nature of Operations	3 Months Ended
Note 1 - Nature of Operations	Mar. 31, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: NATURE OF OPERATIONS Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. The Company is focused on development of its pharmaceutical and drug delivery programs.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Liquidity and Capital Resources	3 Months Ended
Note 2 - Liquidity and Capital Resources	Mar. 31, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2: LIQUIDITY AND CAPITAL RESOURCES The Company has incurred net losses and negative operating cash flows since inception. For the three months ended March 31, 2019, the Company recorded a net loss of approximately $4.1 million and used approximately $2.1 million of cash in operating activities. As of March 31, 2019, the Company had approximately $19.6 million in cash and cash equivalents and working capital of approximately $19.3 million. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and is currently expending funds in research and development activities that are expected to continue to require funding. Management believes the currently available funding will be sufficient to finance the Company’s operations for at least one year from the date of these Condensed Consolidated Financial Statements. However, the Company will likely require additional funding to continue its activities beyond that date. If adequate funds are not available, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned commercial activities. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Accounting Policies	3 Months Ended
Note 3 - Summary of Accounting Policies	Mar. 31, 2019
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: SUMMARY OF ACCOUNTING POLICIES Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S- X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10 -K of the Company for the year ended December 31, 2018. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2019, are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements: In the first quarter of 2019, we adopted Accounting Standards Update (“ASU”) No. 2016 - 02, Lease Accounting Topic 842 : (" Topic 842 ") and recognized on our Condensed Consolidated Balance Sheet $101,000 of lease liabilities with corresponding right-of-use assets for operating leases. The new lease standard requires a lessee to measure its operating lease liabilities at the present value of the remaining minimum lease payments with a discounted cash flow model using the interest rate implicit in the lease. If the implicit interest rate cannot be readily determined, the lessee must use its incremental borrowing rate (“IBR”). If the lessee does not have an IBR, the lessee must use a rate that approximates the rate of interest that the lessee would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. The implicit interest rate was readily determinable for our copier lease; however, we used an IBR to measure our adoption date operating lease liability related to our office space which rate represents our estimated borrowing rate on a secured loan collateralized by similar assets for a similar term. The adoption did not have an impact on the Condensed Consolidated Statements of Cash Flows. As permitted under the standard, we elected prospective application of the new guidance and prior periods continue to be presented in accordance with Accounting Standards Codification ("ASC") Topic 840. Refer to our 2018 Annual Report on Form 10 -K for disclosures required by Topic 840. The new standard provides a number of optional practical expedients in transition. We elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. We did not elect the practical expedient allowing the use-of-hindsight which would require us to reassess the lease term of its leases based on all facts and circumstances through the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to our current contract portfolio. See Note 11, Commitments and Contingencies, of the notes to our unaudited condensed consolidated financial statements for additional discussion of our leases and the amounts recognized in these unaudited condensed consolidated financial statements. On January 1, 2019, we adopted ASU 2018 - 08, Not -for-Profit Entities (Topic 958 ): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made. This ASU affects not -for-profit entities and business entities that receive or make contributions of cash. The ASU clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic 958 or as an exchange transaction subject to other guidance. The adoption did not have any impact on the financial statements. Recent Accounting Pronouncements: In August 2018, the FASB issued ASU No. 2018 - 13, Fair Value Measurement (Topic 820 ): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. Furthermore, an entity is permitted to early adopt any removed or modified disclosures upon issuance of the update and delay adoption of the additional disclosures until their effective date. We do not expect this amendment to have a material impact on our consolidated financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Prepaid Expenses

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Prepaid Expenses [Text Block]

NOTE

PREPAID EXPENSES

Prepaid expenses consisted of the following:

	March 31,		December 31,
	2019		2018
Prepaid insurance	$	234,875	$	160,576
Prepaid research and development		392,894		218,090
Professional services		96,250		110,094
Financial exchange fees		58,685
Prepaid rent		17,100
Retainer and security deposits		14,218		16,718
Other		21,446		4,355
Total prepaid expenses	$	835,468	$	509,833

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Research and Development Tax Rebate Receivable	3 Months Ended
Note 5 - Research and Development Tax Rebate Receivable	Mar. 31, 2019
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 5: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE On May 23, 2017, Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase 1 and Phase 2 Endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the three months ended March 31, 2019 and 2018, the Company incurred qualified R&D expenses of approximately $80,000 and $86,000, respectively. The Company recorded a rebate receivable of approximately $35,000 and $38,000 for the three months ended March 31, 2019 and 2018, respectively and a corresponding credit to R&D expenses. At March 31, 2019, we had a total R&D rebate receivable of approximately $238,000 that includes approximately $203,000 receivable remaining from the year ended December 31, 2018.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Payroll Liabilities

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

NOTE

PAYROLL LIABILITIES

Payroll liabilities consisted of the following:

	March 31, 2019		December 31, 2018
Accrued bonuses	$	646,433	$	697,995
Accrued vacation		162,619		160,740
Accrued payroll		82,706		76,335
Total payroll liabilities	$	891,758	$	935,070

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity	3 Months Ended
Note 7 - Stockholders' Equity	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7: STOCKHOLDERS’ EQUITY The Company is authorized to issue a total of 185,000,000 shares of stock consisting of 175,000,000 shares of common stock, par value $0.18 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750,000 shares of Series A junior participating preferred stock, par value $0.001 per share, 4,000 shares of Series A convertible preferred stock, par value $0.001 per share, and 25,000 shares of Series B convertible preferred stock, par value $0.001 per share, through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock and no shares of Series A convertible preferred stock are issued and outstanding as of March 31, 2019. 2018 Subscription Rights Offering of Units Consisting of Series B Convertible Preferred Stock and Warrants On May 30, 2018, the Company completed a rights offering pursuant to which the Company sold an aggregate of 13,624 units consisting of an aggregate of 13,624 shares of Series B convertible preferred stock and 3,869,216 warrants, with each warrant exercisable for one share of common stock at an exercise price of $4.05 per share (the “2018 Warrants”), resulting in net proceeds to the Company of approximately $12.3 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. Warrants As of March 31, 2019, 1,070,028 warrants to purchase shares of common stock were outstanding. The warrants have an exercise price of $4.05 and expire on May 30, 2022. For the three months ended March 31, 2019, the Company received approximately $11.3 million from exercises of the 2018 Warrants. As a result of the warrant exercises, the Company issued approximately 2.8 million warrants and issued approximately 2.8 million shares of common stock. Conversion of Series B Convertible Preferred Stock During the three months ended March 31, 2019, certain holders of the Series B convertible preferred stock exercised their conversion option and converted an aggregate of 1,677 shares into 476,431 shares of the Company's common stock based on the conversion ratio of approximately 284 shares of common stock for each share of Series B convertible preferred stock.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

NET LOSS PER SHARE

The Company accounts for and discloses net loss per common share in accordance with ASC Topic

260,

Earnings Per Share

. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented they have been excluded from the calculation.

The following table summarizes the Company’s calculation of net loss per common share:

	Three Months Ended March 31,
	2019			2018
Numerator
Net loss attributable to common shareholders	$	(4,073,307	)	$	(1,874,382	)
Denominator
Weighted average common shares outstanding used to compute net loss per share, basic and diluted		6,565,514			220,996
Net loss per share of common stock, basic and diluted:	$	(0.62	)	$	(8.48	)

The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the

three

months ended

March 31, 2019

and

2018

because including them would be anti-dilutive:

	Three Months Ended March 31,
	2019		2018
Options to purchase common stock		783,383		14,473
Series B convertible preferred stock		458,994
Warrants to purchase common stock		3,369,468		76,235
		4,611,845		90,708

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes	3 Months Ended
Note 9 - Income Taxes	Mar. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9: INCOME TAXES Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of March 31, 2019 and December 31, 2018, due to the Company’s continuing operating losses.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 10 - Concentration of Credit Risk	3 Months Ended
Note 10 - Concentration of Credit Risk	Mar. 31, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 10: CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At March 31, 2019 and December 31, 2018, the Company had $18,925,000 and $10,052,000 in excess of the FDIC insured limit, respectively.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Commitments and Contingencies	3 Months Ended
Note 11 - Commitments and Contingencies	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 11: COMMITMENTS AND CONTINGENCIES Lease Commitments As discussed in Note 3, we adopted the requirements of ASU No. 2016 - 02, Lease Accounting: Topic 842 , and all related amendments on January 1, 2019. Prior to January 1, 2019, we accounted for leases in accordance with ASC Topic 840, Leases . In accordance with Topic 842, we evaluate all contractual agreements at inception to determine if they contain a lease. We measure lease liabilities at present value of lease payments not yet paid, using a discounted cash flow model that requires the use of a discount rate, or incremental borrowing rate. Our operating lease assets consist of an office lease and a copier system lease. Our office lease expires in August of 2020 and our copier system lease expires in October of 2021. None of our leases contain options to extend. Total operating lease expense for the three months ended March 31, 2019, was approximately $12,900 and variable lease payments of taxes and insurance were immaterial. As of March 31, 2019, the weighted average remaining lease term was approximately 1.7 years and the weighted average discount rate of our operating leases was 12%. As of March 31, 2019, the future minimum lease payments are approximately $44,000, $44,000 and $12,000 for 2019, 2020 and 2021, respectively. These amounts are net of approximately $12,000 of imputed interest. The cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2019 was approximately $14,600. Litigation and Contingencies We are subject to legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

NOTE

12:

STOCK BASED COMPENSATION

Stock Option and Incentive Plan

September 28, 2010,

the Board of Directors approved the adoption of the

2010

Stock Option and Incentive Plan the (

“2010

Plan”) to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options

may

be granted under the

2010

Plan until

September 2020.

other awards

may

be granted under the

2010

Plan after the date that is

years from the date of stockholder approval. An aggregate of

5,556

shares were initially reserved for issuance in connection with awards granted under the

2010

Plan and on

May 18, 2016,

an additional

11,111

shares were reserved for issuance under the

2010

Plan. On

May 9, 2018,

the stockholders approved an additional

125,000

shares for issuance under the

2010

Plan. On

April 12, 2018,

the stockholders approved an additional

500,000

shares for issuance under the

2010

Plan.

The following table presents the automatic additions to the

2010

Plan since inception pursuant to the “evergreen” terms of the

2010

Plan:

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		7,257
2017		12,623
2018		106,076
2019		233,862
Total additional shares		374,782

The Company did

not

grant options to purchase shares of common stock during the

three

months ended

March 31, 2019

2018.

options were exercised during the

three

months ended

March 31, 2019

2018.

There are

236,430

shares available for grant under the

2010

Plan as of

March 31, 2019.

$275,833

and

$215,139

for the

three

months ended

March 31, 2019

and

2018,

respectively (excluding the liability options discussed below).

	Three Months Ended March 31,
	2019		2018
General and administrative	$	224,676	$	166,701
Research and development		51,157		48,438
Total stock compensation Expense	$	275,833	$	215,139

Options issued and outstanding as of

March 31, 2019,

under the

2010

Plan and their activities during the

three

months then ended are as follows:

	Number of Underlying Shares		Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2019		783,383	$	12.14
Granted
Forfeited
Expired
Outstanding as of March 31, 2019		783,383		12.14		8.92	$	695,400
Exercisable as of March 31, 2019		434,515		19.38		8.84	$	374,063
Vested and expected to vest		783,383	$	12.14		8.92	$	695,400

March 31, 2019,

there were

348,868

unvested options outstanding and the related unrecognized total compensation cost associated with these options was approximately

$876,533.

This expense is expected to be recognized over a weighted-average period of

1.40

years.

2018

Liability Options

June 27, 2018,

the Company granted

2,300,000

options to the Chief Executive Officer (CEO) and

700,000

to the Chief Financial Officer (CFO) (the "Liability Options"). Each option was exercisable for an equivalent number of shares of Company's common stock. The Liability Options were granted pursuant to an option award agreement and were granted outside the Company’s

2010

Plan; however, they were subject to the terms and conditions of the

2010

Plan. On

January 13, 2019,

the Liability Options were canceled.

The Liability Options were exercisable for shares of common stock at an exercise price of

$2.38

per share, which was the fair value on the date of grant. The options had an exercise period of

ten

years from their date of issuance. If at the time the options were exercised the Company could

not

deliver shares of common stock to the optionee including, for example, if there were insufficient shares available under the Plan at the time of exercise, then in lieu of the optionee paying the exercise price and the Company issuing shares of stock, the option only would be exercised on a cash “net basis” so that the Company would pay cash in an amount equal to the excess of the fair value of the common stock over the option exercise price. If there were

not

sufficient shares available under the Plan, the Company would have been obligated to settle these options in cash if they were exercised. Because these options contained provisions that would require the Company to settle the options in cash in an event outside the Company’s control, they were accounted for as liabilities.

The Liability Options were subject to vesting requirements. Twenty-

five

percent of the options were vested as of the grant date,

50%

of the options would have vested quarterly over

two

years, and the remaining

25%

would have vested upon achievement of certain milestones related to clinical trial progress. As of

January 13, 2019,

all of the Liability Options that vested upon achievement of clinical trial milestones were vested. On

January 13, 2019,

the Liability Options were cancelled and at the time of cancellation, there were

1,125,000

unvested Liability Options outstanding.

At the time of cancellation, the fair value of Liability Options at

January 13, 2019,

was calculated using the Black-Scholes option-pricing model applying the following assumptions:

	January 13,
	2019

Risk free interest rate		2.53	%
Expected term (in years)		4.50-5.00
Stock price	$	1.36
Dividend yield			%
Expected volatility		121.0-123.0	%

As a result of the cancellation, the Company recognized all remaining unrecognized compensation expense related to these options of

$1,741,919,

which was included in the following captions in the condensed consolidated statements of operations:

	Period Ended March 31, 2019

General and administrative	$	1,074,183
Research and development		667,736
Total stock compensation expense	$	1,741,919

Also on

January 13, 2019,

at the same time the Liability Options were cancelled, the Company awarded a new option to the CEO to purchase

2,300,000

shares of Common Stock and a new option to the CFO to purchase

800,000

shares of common stock (the

“2019

Options”). The

2019

Options: (i) have an exercise price equal to the fair market value of Common Stock on the date of board of director approval which was

$1.36

per share, (ii) do

not

contain a net cash exercise provision, (iii) are awarded pursuant to the terms and conditions of the

2010

Plan as amended by the Board of Directors on

January 13, 2019,

to include shares issuable upon exercise of the

2019

Options and other changes to the

2010

Plan so that the

2019

Options do

not

conflict with the

2010

Plan (the “Amended Plan”), (iv) vest and are exercisable in accordance with the vesting schedule related to the

2018

Liability Options; provided, however, that the

2019

Options are

not

exercisable unless and until the Company’s stockholders approve the Amended Plan to increase the authorized number of shares available for grant under the Plan and (vi) are subject to and conditioned upon the

2019

Option Agreements with the optionees and the employment agreements with the optionees.

2019

Options.

Accounting treatment

Awards offered under a plan that are subject to shareholder approval are

not

considered granted under GAAP until the approval is obtained, unless such approval is essentially a formality (or perfunctory). For example, if management and board members control sufficient votes to approve the plan, the vote

may

be considered perfunctory. As management and the Company’s Board of Directors do

not

control enough votes to approve the

2019

Options, the

2019

Options are

not

deemed granted under ASC

718.

Cancellation of an award that is

not

accompanied by the concurrent grant are accounted for as a repurchase for

consideration. Accordingly, any previously unrecognized compensation cost is recognized at the cancellation date. On

January 13, 2019,

as noted above, the Company recognized

$1,741,919

of unrecognized compensation cost related to the

2018

Liability Options. Additionally, the fair value of the stock-based compensation liability of

$3,151,944

was reclassified to additional-paid in capital on the cancellation date. If shareholder approval is obtained and a grant date is established for the

2019

Options, the Company will measure and record them as a new grant under ASC

718.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 -Q and Rule 10 - 01 of Regulation S- X. They do not include all information and notes required by GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10 -K of the Company for the year ended December 31, 2018. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2019, are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements: In the first quarter of 2019, we adopted Accounting Standards Update (“ASU”) No. 2016 - 02, Lease Accounting Topic 842 : (" Topic 842 ") and recognized on our Condensed Consolidated Balance Sheet $101,000 of lease liabilities with corresponding right-of-use assets for operating leases. The new lease standard requires a lessee to measure its operating lease liabilities at the present value of the remaining minimum lease payments with a discounted cash flow model using the interest rate implicit in the lease. If the implicit interest rate cannot be readily determined, the lessee must use its incremental borrowing rate (“IBR”). If the lessee does not have an IBR, the lessee must use a rate that approximates the rate of interest that the lessee would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. The implicit interest rate was readily determinable for our copier lease; however, we used an IBR to measure our adoption date operating lease liability related to our office space which rate represents our estimated borrowing rate on a secured loan collateralized by similar assets for a similar term. The adoption did not have an impact on the Condensed Consolidated Statements of Cash Flows. As permitted under the standard, we elected prospective application of the new guidance and prior periods continue to be presented in accordance with Accounting Standards Codification ("ASC") Topic 840. Refer to our 2018 Annual Report on Form 10 -K for disclosures required by Topic 840. The new standard provides a number of optional practical expedients in transition. We elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. We did not elect the practical expedient allowing the use-of-hindsight which would require us to reassess the lease term of its leases based on all facts and circumstances through the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to our current contract portfolio. See Note 11, Commitments and Contingencies, of the notes to our unaudited condensed consolidated financial statements for additional discussion of our leases and the amounts recognized in these unaudited condensed consolidated financial statements. On January 1, 2019, we adopted ASU 2018 - 08, Not -for-Profit Entities (Topic 958 ): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made. This ASU affects not -for-profit entities and business entities that receive or make contributions of cash. The ASU clarifies and improves the scope and accounting guidance to assist entities in evaluating if those transactions should be accounted for as contributions under the scope of Topic 958 or as an exchange transaction subject to other guidance. The adoption did not have any impact on the financial statements. Recent Accounting Pronouncements: In August 2018, the FASB issued ASU No. 2018 - 13, Fair Value Measurement (Topic 820 ): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement , to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. Furthermore, an entity is permitted to early adopt any removed or modified disclosures upon issuance of the update and delay adoption of the additional disclosures until their effective date. We do not expect this amendment to have a material impact on our consolidated financial statements.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 4 - Prepaid Expenses (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

	March 31,		December 31,
	2019		2018
Prepaid insurance	$	234,875	$	160,576
Prepaid research and development		392,894		218,090
Professional services		96,250		110,094
Financial exchange fees		58,685
Prepaid rent		17,100
Retainer and security deposits		14,218		16,718
Other		21,446		4,355
Total prepaid expenses	$	835,468	$	509,833

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 6 - Payroll Liabilities (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	March 31, 2019		December 31, 2018
Accrued bonuses	$	646,433	$	697,995
Accrued vacation		162,619		160,740
Accrued payroll		82,706		76,335
Total payroll liabilities	$	891,758	$	935,070

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended March 31,
	2019			2018
Numerator
Net loss attributable to common shareholders	$	(4,073,307	)	$	(1,874,382	)
Denominator
Weighted average common shares outstanding used to compute net loss per share, basic and diluted		6,565,514			220,996
Net loss per share of common stock, basic and diluted:	$	(0.62	)	$	(8.48	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended March 31,
	2019		2018
Options to purchase common stock		783,383		14,473
Series B convertible preferred stock		458,994
Warrants to purchase common stock		3,369,468		76,235
		4,611,845		90,708

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

January 1,	Number of shares
2012		2,502
2013		2,871
2014		4,128
2015		5,463
2016		7,257
2017		12,623
2018		106,076
2019		233,862
Total additional shares		374,782

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
	2019		2018
General and administrative	$	224,676	$	166,701
Research and development		51,157		48,438
Total stock compensation Expense	$	275,833	$	215,139

	Period Ended March 31, 2019

General and administrative	$	1,074,183
Research and development		667,736
Total stock compensation expense	$	1,741,919

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Underlying Shares		Weighted- Average Exercise Price Per Share		Weighted- Average Contractual Life Remaining in Years		Aggregate Intrinsic Value
Outstanding as of January 1, 2019		783,383	$	12.14
Granted
Forfeited
Expired
Outstanding as of March 31, 2019		783,383		12.14		8.92	$	695,400
Exercisable as of March 31, 2019		434,515		19.38		8.84	$	374,063
Vested and expected to vest		783,383	$	12.14		8.92	$	695,400

Liability Options [Member]

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	January 13,
	2019

Risk free interest rate		2.53	%
Expected term (in years)		4.50-5.00
Stock price	$	1.36
Dividend yield			%
Expected volatility		121.0-123.0	%

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 2 - Liquidity and Capital Resources (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Net Income (Loss) Attributable to Parent, Total	$ (4,073,307)	$ (1,874,382)
Net Cash Provided by (Used in) Operating Activities, Total	(2,148,956)	(2,386,882)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	19,568,247	$ 4,779,519	$ 10,380,493
Working Capital	$ 19,300,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Accounting Policies (Details Textual) - USD ($)	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Liability, Total		$ 101,000
Operating Lease, Right-of-Use Asset	$ 88,103	$ 101,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Prepaid insurance	$ 234,875	$ 160,576
Prepaid research and development	392,894	218,090
Professional services	96,250	110,094
Financial exchange fees	58,685
Prepaid rent	17,100
Retainer and security deposits	14,218	16,718
Other	21,446	4,355
Total prepaid expenses	$ 835,468	$ 509,833

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 5 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	May 23, 2017
Research and Development Expense, Total	$ 1,451,236	$ 470,976
Increase (Decrease) in Research and Development Tax Rebate Receivable	(280,242)	37,595
Research and Development Tax Rebate Receivable	237,856		$ 518,098
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar				$ 0.435
Research and Development Expense, Total	80,000	86,000
Increase (Decrease) in Research and Development Tax Rebate Receivable	35,000	$ 38,000
Research and Development Tax Rebate Receivable	$ 238,000		$ 203,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Accrued bonuses	$ 646,433	$ 697,995
Accrued vacation	162,619	160,740
Accrued payroll	82,706	76,335
Total payroll liabilities	$ 891,758	$ 935,070

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Details Textual) - USD ($)		3 Months Ended
	May 30, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Number of Shares Authorized to Issue		185,000,000
Common Stock, Shares Authorized		175,000,000		175,000,000
Common Stock, Par or Stated Value Per Share		$ 0.18		$ 0.18
Preferred Stock, Shares Authorized		10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total		702		2,379
Class of Warrant or Right, Outstanding		1,070,028
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.05
Proceeds from Warrant Exercises		$ 11,336,710
Class of Warrant or Right, Exercised During Period		2,800,000
Stock Issued During Period, Shares, Warrant Exercised		2,800,000
Preferred Stock, Shares Outstanding, Ending Balance		702		2,379
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted		1,677
Conversion of Stock, Shares Issued		476,431
Convertible Preferred Stock, Shares Issued upon Conversion		284
The 2018 Subscription Rights Offering [Member]
Number of Units Sold	13,624
Proceeds from Issuance of Stock units	$ 12,300,000
The 2018 Subscription Rights Offering [Member] \| The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding	3,869,216
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.05
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized		750,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Shares Issued, Total		0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		4,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance		0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		25,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Series B Convertible Preferred Stock [Member] \| The 2018 Subscription Rights Offering [Member]
Stock Issued During Period, Shares, New Issues	13,624

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net loss attributable to common shareholders	$ (4,073,307)	$ (1,874,382)
Weighted average shares outstanding - basic and diluted (in shares)	6,565,514	220,996
Loss per common share - basic and diluted (in dollars per share)	$ (0.62)	$ (8.48)

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Number of potential common shares excluded (in shares)	4,611,845	90,708
Share-based Payment Arrangement, Option [Member]
Number of potential common shares excluded (in shares)	783,383	14,473
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	458,994
Warrant [Member]
Number of potential common shares excluded (in shares)	3,369,468	76,235

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Expense (Benefit), Total	$ 0	$ 0

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 10 - Concentration of Credit Risk (Details Textual) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Cash, Uninsured Amount	$ 18,925,000	$ 10,052,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 11 - Commitments and Contingencies (Details Textual)	3 Months Ended
	Mar. 31, 2019 USD ($)
Operating Lease, Expense	$ 12,900
Operating Lease, Weighted Average Remaining Lease Term	1 year 255 days
Operating Lease, Weighted Average Discount Rate, Percent	12.00%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 44,000
Lessee, Operating Lease, Liability, Payments, Due Year Two	44,000
Lessee, Operating Lease, Liability, Payments, Due Year Three	12,000
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	12,000
Operating Lease, Payments	$ 14,600

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation (Details Textual) - USD ($)							3 Months Ended
	Jan. 13, 2019	Jun. 27, 2018	May 09, 2018	Apr. 12, 2018	May 18, 2016	Sep. 28, 2010	Mar. 31, 2019	Mar. 31, 2018
Adjustments to Additional Paid in Capital, Transfer of Stock-based Compensation Liability Upon Option Cancellation	$ 3,151,944						$ 3,151,944
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense							$ 275,833	$ 215,139
Liability Options [Member]
Share-based Payment Arrangement, Expense	$ 1,741,919
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance	1,125,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 2.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Liability Options [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Liability Options [Member] \| Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years
Liability Options [Member] \| Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Liability Options [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,300,000
Liability Options [Member] \| Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		700,000
The 2019 Options [Member[
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.36
The 2019 Options [Member[ \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,300,000
The 2019 Options [Member[ \| Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	800,000
The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Period for Granting Shares						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								0
The 2010 Stock Option and Incentive Plan [Member] \| Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						5,556
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			125,000	500,000	11,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							236,430
Share-based Payment Arrangement, Expense							$ 275,833	$ 215,139
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance							348,868
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount							$ 876,533
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition							1 year 146 days

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) - shares	3 Months Ended	12 Months Ended							87 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2019
The 2010 Stock Option and Incentive Plan [Member]
Total additional shares (in shares)	233,862	106,076	12,623	7,257	5,463	4,128	2,871	2,502	374,782

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)		3 Months Ended
	Jan. 13, 2019	Mar. 31, 2019	Mar. 31, 2018
Liability Options [Member]
Total stock compensation expense	$ 1,741,919
Share-based Payment Arrangement, Option [Member]
Total stock compensation expense		$ 275,833	$ 215,139
General and Administrative Expense [Member] \| Liability Options [Member]
Total stock compensation expense	1,074,183
General and Administrative Expense [Member] \| Share-based Payment Arrangement, Option [Member]
Total stock compensation expense		224,676	166,701
Research and Development Expense [Member] \| Liability Options [Member]
Total stock compensation expense	$ 667,736
Research and Development Expense [Member] \| Share-based Payment Arrangement, Option [Member]
Total stock compensation expense		$ 51,157	$ 48,438

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation - Stock Option Activity (Details) - The 2010 Stock Option and Incentive Plan [Member]	3 Months Ended
	Mar. 31, 2019 USD ($) $ / shares shares
Outstanding, shares (in shares) \| shares	783,383
Outstanding, Weighted average exercise price per share (in dollars per share) \| $ / shares	$ 12.14
Outstanding, shares (in shares) \| shares	783,383
Outstanding, Weighted average exercise price per share (in dollars per share) \| $ / shares	$ 12.14
Outstanding, weighted average contractual life remaining in years (Year)	8 years 335 days
Outstanding, aggreate instrinsic value \| $	$ 695,400
Exercisable, shares (in shares) \| shares	434,515
Exercisable, Weighted average exercise price per share (in dollars per share) \| $ / shares	$ 19.38
Exercisable, weighted average contractual life remaining in years (Year)	8 years 306 days
Exercisable, aggreate instrinsic value \| $	$ 374,063
Vested and expected to vest, shares (in shares) \| shares	783,383
Vested and expected to vest, Weighted average exercise price per share (in dollars per share) \| $ / shares	$ 12.14
Vested and expected to vest, weighted average contractual life remaining in years (Year)	8 years 335 days
Vested and expected to vest, aggreate instrinsic value \| $	$ 695,400

XML 50 R39.htm IDEA: XBRL DOCUMENT

Note 12 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details)	Jan. 13, 2019 $ / shares
Dividend yield
Liability Options [Member]
Risk free interest rate	2.53%
Stock price (in dollars per share)	$ 1.36

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 98 176 1 false 26 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.atossagenetics.com/20190331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.atossagenetics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.atossagenetics.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.atossagenetics.com/20190331/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.atossagenetics.com/20190331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudied) Sheet http://www.atossagenetics.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudied Condensed Consolidated Statements of Cash Flows (Unaudied) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Operations Sheet http://www.atossagenetics.com/20190331/role/statement-note-1-nature-of-operations- Note 1 - Nature of Operations Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Liquidity and Capital Resources Sheet http://www.atossagenetics.com/20190331/role/statement-note-2-liquidity-and-capital-resources Note 2 - Liquidity and Capital Resources Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Summary of Accounting Policies Sheet http://www.atossagenetics.com/20190331/role/statement-note-3-summary-of-accounting-policies- Note 3 - Summary of Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Prepaid Expenses Sheet http://www.atossagenetics.com/20190331/role/statement-note-4-prepaid-expenses- Note 4 - Prepaid Expenses Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Research and Development Tax Rebate Receivable Sheet http://www.atossagenetics.com/20190331/role/statement-note-5-research-and-development-tax-rebate-receivable- Note 5 - Research and Development Tax Rebate Receivable Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Payroll Liabilities Sheet http://www.atossagenetics.com/20190331/role/statement-note-6-payroll-liabilities- Note 6 - Payroll Liabilities Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Stockholders' Equity Sheet http://www.atossagenetics.com/20190331/role/statement-note-7-stockholders-equity Note 7 - Stockholders' Equity Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Net Loss Per Share Sheet http://www.atossagenetics.com/20190331/role/statement-note-8-net-loss-per-share- Note 8 - Net Loss Per Share Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Income Taxes Sheet http://www.atossagenetics.com/20190331/role/statement-note-9-income-taxes Note 9 - Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Concentration of Credit Risk Sheet http://www.atossagenetics.com/20190331/role/statement-note-10-concentration-of-credit-risk- Note 10 - Concentration of Credit Risk Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Commitments and Contingencies Sheet http://www.atossagenetics.com/20190331/role/statement-note-11-commitments-and-contingencies- Note 11 - Commitments and Contingencies Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Stock Based Compensation Sheet http://www.atossagenetics.com/20190331/role/statement-note-12-stock-based-compensation- Note 12 - Stock Based Compensation Notes 18 false false R19.htm 018 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.atossagenetics.com/20190331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.atossagenetics.com/20190331/role/statement-note-3-summary-of-accounting-policies- 19 false false R20.htm 019 - Disclosure - Note 4 - Prepaid Expenses (Tables) Sheet http://www.atossagenetics.com/20190331/role/statement-note-4-prepaid-expenses-tables Note 4 - Prepaid Expenses (Tables) Tables http://www.atossagenetics.com/20190331/role/statement-note-4-prepaid-expenses- 20 false false R21.htm 020 - Disclosure - Note 6 - Payroll Liabilities (Tables) Sheet http://www.atossagenetics.com/20190331/role/statement-note-6-payroll-liabilities-tables Note 6 - Payroll Liabilities (Tables) Tables http://www.atossagenetics.com/20190331/role/statement-note-6-payroll-liabilities- 21 false false R22.htm 021 - Disclosure - Note 8 - Net Loss Per Share (Tables) Sheet http://www.atossagenetics.com/20190331/role/statement-note-8-net-loss-per-share-tables Note 8 - Net Loss Per Share (Tables) Tables http://www.atossagenetics.com/20190331/role/statement-note-8-net-loss-per-share- 22 false false R23.htm 022 - Disclosure - Note 12 - Stock Based Compensation (Tables) Sheet http://www.atossagenetics.com/20190331/role/statement-note-12-stock-based-compensation-tables Note 12 - Stock Based Compensation (Tables) Tables http://www.atossagenetics.com/20190331/role/statement-note-12-stock-based-compensation- 23 false false R24.htm 023 - Disclosure - Note 2 - Liquidity and Capital Resources (Details Textual) Sheet http://www.atossagenetics.com/20190331/role/statement-note-2-liquidity-and-capital-resources-details-textual Note 2 - Liquidity and Capital Resources (Details Textual) Details http://www.atossagenetics.com/20190331/role/statement-note-2-liquidity-and-capital-resources 24 false false R25.htm 024 - Disclosure - Note 3 - Summary of Accounting Policies (Details Textual) Sheet http://www.atossagenetics.com/20190331/role/statement-note-3-summary-of-accounting-policies-details-textual Note 3 - Summary of Accounting Policies (Details Textual) Details 25 false false R26.htm 025 - Disclosure - Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) Sheet http://www.atossagenetics.com/20190331/role/statement-note-4-prepaid-expenses-schedule-of-prepaid-expenses-details Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) Details 26 false false R27.htm 026 - Disclosure - Note 5 - Research and Development Tax Rebate Receivable (Details Textual) Sheet http://www.atossagenetics.com/20190331/role/statement-note-5-research-and-development-tax-rebate-receivable-details-textual Note 5 - Research and Development Tax Rebate Receivable (Details Textual) Details http://www.atossagenetics.com/20190331/role/statement-note-5-research-and-development-tax-rebate-receivable- 27 false false R28.htm 027 - Disclosure - Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) Sheet http://www.atossagenetics.com/20190331/role/statement-note-6-payroll-liabilities-schedule-of-payroll-liabilities-details Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) Details 28 false false R29.htm 028 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) Sheet http://www.atossagenetics.com/20190331/role/statement-note-7-stockholders-equity-details-textual Note 7 - Stockholders' Equity (Details Textual) Details http://www.atossagenetics.com/20190331/role/statement-note-7-stockholders-equity 29 false false R30.htm 029 - Disclosure - Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) Sheet http://www.atossagenetics.com/20190331/role/statement-note-8-net-loss-per-share-schedule-of-earnings-per-share-details Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) Details 30 false false R31.htm 030 - Disclosure - Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) Sheet http://www.atossagenetics.com/20190331/role/statement-note-8-net-loss-per-share-schedule-of-antidilutive-securities-details Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) Details 31 false false R32.htm 031 - Disclosure - Note 9 - Income Taxes (Details Textual) Sheet http://www.atossagenetics.com/20190331/role/statement-note-9-income-taxes-details-textual Note 9 - Income Taxes (Details Textual) Details http://www.atossagenetics.com/20190331/role/statement-note-9-income-taxes 32 false false R33.htm 032 - Disclosure - Note 10 - Concentration of Credit Risk (Details Textual) Sheet http://www.atossagenetics.com/20190331/role/statement-note-10-concentration-of-credit-risk-details-textual Note 10 - Concentration of Credit Risk (Details Textual) Details http://www.atossagenetics.com/20190331/role/statement-note-10-concentration-of-credit-risk- 33 false false R34.htm 033 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual) Sheet http://www.atossagenetics.com/20190331/role/statement-note-11-commitments-and-contingencies-details-textual Note 11 - Commitments and Contingencies (Details Textual) Details http://www.atossagenetics.com/20190331/role/statement-note-11-commitments-and-contingencies- 34 false false R35.htm 034 - Disclosure - Note 12 - Stock Based Compensation (Details Textual) Sheet http://www.atossagenetics.com/20190331/role/statement-note-12-stock-based-compensation-details-textual Note 12 - Stock Based Compensation (Details Textual) Details http://www.atossagenetics.com/20190331/role/statement-note-12-stock-based-compensation-tables 35 false false R36.htm 035 - Disclosure - Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) Sheet http://www.atossagenetics.com/20190331/role/statement-note-12-stock-based-compensation-additional-shares-authorized-details Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) Details 36 false false R37.htm 036 - Disclosure - Note 12 - Stock Based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.atossagenetics.com/20190331/role/statement-note-12-stock-based-compensation-stockbased-compensation-expense-details Note 12 - Stock Based Compensation - Stock-based Compensation Expense (Details) Details 37 false false R38.htm 037 - Disclosure - Note 12 - Stock Based Compensation - Stock Option Activity (Details) Sheet http://www.atossagenetics.com/20190331/role/statement-note-12-stock-based-compensation-stock-option-activity-details Note 12 - Stock Based Compensation - Stock Option Activity (Details) Details 38 false false R39.htm 038 - Disclosure - Note 12 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details) Sheet http://www.atossagenetics.com/20190331/role/statement-note-12-stock-based-compensation-valuation-assumptions-for-liability-options-details Note 12 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details) Details 39 false false All Reports Book All Reports atos-20190331.xml atos-20190331.xsd atos-20190331_cal.xml atos-20190331_def.xml atos-20190331_lab.xml atos-20190331_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true ZIP 56 0001437749-19-009666-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-19-009666-xbrl.zip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end